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CHAPTER 1 
Outline of the thesis 
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Shortly after the introduction of antibiotics for treatment of Gram-negative bacterial 
infections, reports were published concerning clinical deterioration of the host after 
the first antibiotic dose. Several years later, it was suspected that this phenomenon 
could be attributed to an antibiotic-induced release of toxic bacterial products, 
especially endotoxin or lipopolysaccharide (LPS). Endotoxin is the central mediator in 
the pathogenesis of Gram-negative sepsis and its inflammatory response. Mediators 
of this inflammatory response, like the cytokines TNF-α or IL-6, augment host 
defence. However, an exaggerated release, as shown during exposure to high 
endotoxin concentrations, may cause clinical deterioration, leading to shock and 
death. 
The present thesis contains various in-vitro and in-vivo studies dealing with the 
effects of initial antibiotic treatment of Gram-negative sepsis on bacteria and hosts. 
This thesis is based upon a multitude of studies of increasing complexity. An over-
view is given in Table 1., listing several study key features. 
Chapter 2 provides the reader with a general introduction of the concept of antibi-
otic treatment of sepsis, with specific attention to the effects of antibiotic choice and 
dosing schedule with regard to bacterial morphology and endotoxin release, as well 
as its possible clinical effects on sepsis patients. Abnormal bacterial morphologies, 
such as filaments and spheroplasts, that may be induced by antibiotics, are intro-
duced, and the possible subsequent effects on endotoxin liberation are discussed. 
The mechanism by which antibiotics may induce bacterial morphology changes, in 
particular by their binding capacities to bacterial Penicillin Binding Proteins (PBPs), 
will also be reviewed. Finally, this chapter includes a short historical overview of 
studies related to this topic and a summary of recent human studies on this subject. 
In chapter 3, we address the issue to what extent various antibiotics differ with 
regard to endotoxin-releasing capacity in-vitro. Since not only antibiotic class and 
type, but also dose regimen can be relevant, studies with an in-vitro dilution model 
were aimed to explore this topic in-depth. Escherichia coli and Pseudomonas aerugi-
nosa strains were exposed to varying dosing schedules of ceftazidime, aztreonam 
and imipenem. These ß-lactams show differing affinities for PBPs. In chapter 4, 
studies on another ß-lactam antibiotic, meropenem, which has specific inhibitory 
efffects on two bacterial PBP subtypes, i.e. PBP-2 and PBP-3, are presented. Mor-
phology of Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae 
strains, exposed to several concentrations of meropenem is carefully investigated, 
focusing on the formation of bacterial filaments. 
Antibiotics like ceftazidime and cefotaxime are described in the literature as dose-
dependent PBP-1 and PBP-3 binding antibiotics. Nevertheless, exact data on the 
concentrations at which PBP-1 or PBP-3 effects predominate are lacking. In chapter 
5 we ask the question whether morphological changes are dependent on the concen-
trations of these antibiotics. In total, 37 strains of different bacterial families (Entero-
bacteriaceae, Pseudomonadiae and Neisseriae), with various levels of resistance to 
ceftazidime and cefotaxime were tested. Also 14 strains of Enterobacteriaceae 
producing extended spectrum ß-lactamase (ESBL) were included in this study. 
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To study the consequences of ß-lactam-induced morphological changes of bacteria 
in-vivo, we developed a murine thigh infection model. This murine thigh infection 
model is used in the studies described in chapters 6 to 9. 
In the first experiments, described in chapter 6, we studied local and systemic 
endotoxin concentrations, circulating cytokines, morphology and bacterial dissemina-
tion characteristics of in-vitro induced filaments and spheroplasts injected in mice 
(Fig 1.).  
 
 
 
Figure 1. Scheme of murine experiments with in-vitro induced filaments, 
spheroplasts and rod-shaped bacilli 
 
To induce morphologically altered bacteria in neutropenic mice in-vivo, we made 
some adjustments in the model. The results of this study comparing the bacterial 
morphology changes, endotoxin release, and cytokine induction by ceftazidime, 
aztreonam, imipenem and meropenem in mice are presented in chapter 7. 
 
 
 
Figure 2. Scheme of murine experiments with in-vivo  
induced filaments, spheroplasts or rod-shaped bacilli 
Meropenem (0.5 x MIC)
4 hours incubation, washing
E.coli 25922
2 colonies
Overnight incubation and dilution: 106 cfu/mL
Ceftazidime (0.5 x MIC)
4 hours incubation, washing
Saline
4 hours incubation, washing
Injection filaments in 
thigh muscle
Injection spheroplasts in 
thigh muscle
Injection rods in thigh
muscle
E. coli or P. aeruginosa cultures
106 cfu/mL
Injection im or ip, incubation 2 h
Bolus or continuous antibiotics iv in tail vein
After 4 hours: filaments, spheroplasts or rods im/ip
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In chapter 8 we compare continuous and bolus intravenous ceftazidime versus 
meropenem treatment in murine Pseudomonas aeruginosa and Escherichia coli 
sepsis (Fig 2. and 3.), to investigate whether variation of PBP-affinity, antibiotic dose 
or dosing schedule influences bacterial morphology, cytokine responses and bacterial 
killing. In chapter 9, effects of exposure of bacterial filaments to further antibiotic 
therapy are described.  
Chapter 10 contains a summary and a general discussion on the subject of the 
thesis. 
 
 
 
 
Figure 3. Anaesthesized mice during continuous infusions in the tail vein
Full colour illustration on page 129 
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CHAPTER 2 
Introduction: 
Bacteria, antibiotics and host factors in 
the initial phase of sepsis treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Updated and extended from: 
Effects of antibiotics on endotoxin release 
Dofferhoff ASM, Buijs J 
Yearbook of Intensive Care and Emergency Medicine 1995; 465-472. 
 
Dose and type dependent antibiotic induced endotoxin release 
Dofferhoff ASM, Buijs J 
In: The immune consequences of trauma, shock and sepsis, mechanisms and thera-
peutic approaches. E. Faist et al. (Eds) 1996; 2(2): 741-747. 
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2.1 Sepsis 
Sepsis or septic shock is a serious life-threatening condition, referring to a constella-
tion of clinical signs, including fever (or hypothermia), organ dysfunction, hypoten-
sion, and shock. This severe process of tissue injury is triggered by several exogenic 
and endogenic mediators at the level of the microvasculature of vital organs.1 The 
clinical syndrome is responsible for 40% of ICU stay.2 A large retrospective study of 
more than 33 741 patients in Australia revealed that Gram-negative bacteria are the 
causative organisms in 20% of cases.3 The mortality rate due to severe Gram-
negative infections, particularly those associated with multiple organ dysfunction, is 
still up to 56%, despite important advances in antimicrobial therapy and supportive 
care.4-6 Early and effective treatment, preventing severe inflammation and concomi-
tant signs of organ dysfunction, seems to be of critical importance in successful 
treatment of Gram-negative sepsis. 
2.2 Gram-negative bacteria 
 
 
Figure 1. Schematic representation of the structure of Gram-negative bacilli 
 
 
Gram-negative bacteria (Fig 1.) are composed of a rigid cell envelope, characterized 
by a multilamellar structure. The inner membrane surrounds the cytoplasm, which 
contains a single double-stranded DNA-molecule. This cytoplasmic membrane con-
sists of a phospholipid bilayer, with interspersed proteins. The outer membrane 
consists of an inner leaflet, consisting of a thin peptidoglycan layer along with a 
periplasmic space. This peptidoglycan is an extensively cross-linked polymer, giving 
the organism its rigid shape. The outer membrane consists of another phospholipid 
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bilayer with intercalation of a number of elements, such as lipopolysaccharides (LPS, 
endotoxin), lipoproteins and porin proteins.7,8 LPS is the major constituent of this 
outer membrane, covering approximately 75% of the outer surface, while the rest is 
mainly covered by porin proteins, forming small channels for hydrophilic diffusion 
through the outer membrane. 9 
2.3 Endotoxin 
Endotoxin or lipopolysaccharide (Fig 2.), discovered in 1892 by Richard Pfeiffer, has 
been recognized as the most important mediator in the pathogenesis of Gram-
negative sepsis.10,11 On each bacterial cell, approximately 3-4 million molecules of 
LPS are present. LPS is a complex phospholipid with a non-repeating “core” oligosac-
charide and a distal polysaccharide.  
 
 
 
 
Figure 2. Gram-negative bacterial endotoxin (lipopolysaccharide, LPS) 
Full colour illustration on page 129 
 
 
The most important parts of the LPS-molecule are: 
I. The lipid A component, which is the primary immunostimulatory centre of LPS, 
causing activation of innate immune responses.12-14 Lipid A is connected to the outer 
and inner core oligosaccharides. 
II. The inner core oligosaccharide, which consists of two sugars: heptose and 2-keto 
3-deoxy-D-manno-octulosonate (KDO), which are mainly responsible for bacterial 
growth capacities.15 
III. The third part of the molecule is the O-antigenic polysaccharide.9 The structural 
diversity of the O-polysaccharide defines the O-antigen specificity, used in serological 
classifications. The remarkable structural diversity of capsular polysaccharides is 
illustrated by the fact that almost 80 different capsular serotypes in Escherichia coli 
are recognized.16 These O-polysaccharides play a role as quite variable virulence 
factors, especially during the activation of the alternative complement cascade.17 
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Figure 3. Schematic representation of the E.coli envelope14 
Abbreviations: LPS: lipopolysaccharide; MDO: membrane-derived oligosaccharides; 
Kdo: 3-deoxy-d-manno-oct-2-ulosonic acid; PPEtn: phosphoethanolamine  
Full colour illustration on page 130 
 
 
LPS of Gram-negative bacilli binds to lipopolysaccharide-binding protein (LBP) and 
CD14, the pattern recognition receptor and binding site for LPS, expressed by mono-
cytes and macrophages. CD14 lacks a transmembrane signalling domain; through 
binding to CD14 and LBP, endotoxin activates Toll-like receptors, especially Toll-like 
receptor-4 (TLR-4), a signal-transducing integral membrane protein located on the 
surface of immune cells.1,18-20 Binding of TLR-4 activates intracellular signal-
transduction pathways that lead to the activation of cytosolic nuclear factor κB (NF-
κB). Activated NF-κB moves from the cytoplasm to the nucleus, binds to transcription 
initiation sites, and increases the transcription of cytokines such as tumour necrosis 
factor-α (TNF-α), interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and interleukin-10 (IL-
10). These are the first steps of a complex cascade, eventually leading to the clinical 
symptoms of infection. Cytokine induction and clinical symptoms like fever, flu-like 
symptoms and cardiovascular changes, can also be induced in healthy volunteers, by 
administration of isolated LPS-molecules.21 
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2.4 Pro-inflammatory cytokines 
The most important pro-inflammatory mediators or cytokines in human septicemia 
are TNF-α, IL-1, and IL-6.22 These cytokines play a role in complex cascades regulat-
ing many biological functions in health and disease: pro-inflammatory cytokines 
activate the adaptive immune response, but may also cause both direct and indirect 
injury to the host. Pro-inflammatory cytokines activate endothelial cells by up-
regulating adhesion receptors and injure endothelial cells by activating neutrophils, 
monocytes, macrophages, and platelets to bind to endothelial cells. These effector 
cells subsequently release mediators such as proteases, oxidants, prostaglandins, 
and leukotrienes, which injure endothelial cells, leading to increased permeability, 
vasodilation, and alteration of the procoagulant-anticoagulant balance (Fig 4.). In low 
concentrations, pro-inflammatory cytokines augment host defense.23-27 However, an 
exaggerated effect, as can be triggered by exposure to an overload of endotoxin, 
may lead to severe pathophysiological reactions resulting in shock and death.28-31 
 
 
Figure 4. Scheme of inflammatory responses in sepsis1 
Full colour illustration on page 130 
 
2.5 Penicillin-Binding Proteins 
Gram-negative bacteria are protected and shaped by a rigid shell of peptidoglycan, 
which is constructed and maintained by a diverse set of enzymes, among which are 
the penicillin-binding proteins (PBPs).32 PBPs are anchored in the cytoplasmic mem-
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branes of bacteria. PBPs, or their peptidoglycan products, do have significant biologi-
cal functions, including roles in determination of cell shape, phage resistance, induc-
tion of capsule synthesis, and regulation of autolysis. PBPs are divided into high 
molecular weight (HMW)-PBPs (numbered 1-3) and low molecular weight (LMW)-
PBPs (numbered 4-7). The function of the LMW-PBPs is still unclear. HMW-PBPs are 
binding sites for ß-lactam antibiotics. Although a great deal has been learned about 
how these proteins synthesize and modify peptidoglycan, many of the physiological 
functions of bacterial PBPs remain enigmatic. 
Each ß-lactam antibiotic has its own, characteristic affinity for HMW-PBPs. When an 
antibiotic binds to a PBP, the function of the latter is blocked. Depending on the 
binding site, that particular antibiotic may cause specific morphological changes in 
the bacteria exposed, which is related to the enzymatic step in cell synthesis that is 
inhibited.33 Inhibition of PBP-1 is associated with rapid bacterial killing and lysis, 
whereas inhibition of PBP-2 induces spherical bacteria, called spheroplasts. PBP-3-
inhibition is associated with formation of long bacterial filaments, by the inability to 
septate after augmentation of the cell-mass.34-36 
The PBP-3/-2 and PBP-3/-1 inhibition ratios of a specific ß-lactam antibiotic will 
influence the length of rods and filaments.37 
Some ß-lactams, like cefotaxime, ceftazidime or cefuroxime, have dose-dependent 
affinities for PBPs. Higher concentrations lead to PBP-1 inhibition and concomitant 
rapid bacterial lysis, without preceding morphological changes. When bacteria are 
exposed to lower concentrations, PBP-3 inibition predominates, leading to filament 
formation. 
2.6 Antibiotic-induced endotoxin release and morphological 
changes 
Small amounts of endotoxin (LPS) molecules are liberated from the cell wall during 
normal bacterial growth. However, they may be liberated in high amounts when 
bacteria are lysed by antibiotic exposure. By this exaggerated release, endotoxin 
molecules can play an ambiguous role during sepsis treatment. 
Jarisch was the first who reported an unexpected and alarming clinical deterioration 
(fever, shock) of patients after initiation of treatment with arsenic-containing medica-
tions in syphilis. This phenomenon was named after him: the “Jarisch-Herxheimer 
reaction”.38 A comparable reaction, even leading to death after a loading dose, was 
observed during treatment of Borrelia-infections, typhoid fever and brucellosis with 
chloramphenicol, penicillin or tetracyclins.39-43 
After publication of a study with an approach of “frappez doucement”, i.e. a gradual 
dose increment at the initiation of therapy, which reduced the mortality of Gram-
negative shock, Reilly suggested that the desire to “frappez fort et vite” should be 
resisted.44 This observation was confirmed and reemphasized by Hopkin et al. who 
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reported two fatalities in patients with suspected bacteremia shortly after the initia-
tion of antibiotic treatment.45,46 In early years it was already suggested, that release 
of bacterial endotoxins might be responsible for this sudden and intriguing deteriora-
tion of patients after initiation of antibiotic therapy. Many studies confirmed the 
endotoxin liberating effect of penicillin,47 moxalactam,48 cefotaxime,49 the aminogly-
cosides (kanamycin50, gentamicin48,24,31), several quinolones51,52,53 and chlorampheni-
col.48,49 In general, it was demonstrated that the use of antibiotics leading to degra-
dation of bacterial cell walls (ß-lactam antibiotics) was related to higher endotoxin 
releases compared with the use of antibiotics with other mechanisms of action, 
initially leaving the cell wall intact.48 
More recently, the antibiotic-induced endotoxin release during exposure of E. coli 
cultures to various antibiotics in-vitro was studied.54 Total endotoxin concentrations 
increased moderately after 4 h of incubation with ceftazidime, tobramycin or the 
combination tobramycin/cefuroxime, whereas monotherapy with cefuroxime or 
aztreonam induced a late, but very high (up to 222-fold) increase of total and free 
endotoxin, reflecting the total endotoxin content and the extent of bacteriolysis, 
respectively. This observation of the late peak was attributed to the formation of long 
bacterial filamentous structures leading to a postponed cell lysis, with delayed, but 
massive endotoxin liberation. The potency of ß-lactam-induced endotoxin-release 
was demonstrated to depend on the relative affinity for PBP-1, PBP-2 and PBP-
3.33,37,54,55 
The influence of antibiotic-induced release of endotoxin from in-vitro cultured E. coli 
on cytokine production by human monocytes was also studied.56 After 24 h of 
incubation, a profound increase of TNF-α production was noticed in cefuroxime and 
aztreonam treated cultures, compared with ceftazidime or imipenem treated cultures, 
suggesting that filament formation might be related to an increased cytokine reponse 
of host immune cells. This cefuroxime-induced release of TNF-α could be prevented 
by addition of tobramycin, which led to bacterial lysis, without preceding filament 
formation. Interestingly, in low-dose cefuroxime- or low-dose ceftazidime-treated 
isolates, incubation of monocytes also resulted in significantly higher concentrations 
of TNF-α, compared with imipenem- or high-dose ceftazidime-treated cultures. 
Again, this was attributed to massive filament formation, observed in those cultures. 
Finally, it should be remembered, that exposure of Gram-negative bacteria to low 
dose ß-lactams not only changes the endotoxin-releasing capacity, but also alters 
other virulence factors like migration and susceptibility to phagocytosis.57-60 
2.7 Animal studies 
Evidence that antibiotic therapy can promote endotoxin release in-vivo was first 
provided by studies in rabbits infected experimentally with E. coli.48,49 Rokke et al.24 
demonstrated endotoxin liberation during gentamicin treatment in an experimental 
porcine septicemia model, which was related to a significant reduction of cardiac 
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performance. Benzylpenicillin-treatment of murine intraperitoneal infections with 
endotoxin-liberating and non-endotoxin-liberating Neisseria meningitidis strains, 
resulted in significant differences in mortality, which could also be related to antibi-
otic-induced endotoxin release.23 
In studies of E. coli peritonitis in rats, decreasing levels of viable counts after treat-
ment with ceftazidime or aztreonam were observed, accompanied by increased levels 
of free endotoxin and plasma IL-6.56 This is in line with antibiotic-induced formation 
of bacterial filaments, since filament formation rapidly reduces the number of cfu by 
the inability of bacteria to septate after multiplication of their cell-mass. The accom-
panying endotoxin rise also suggests that filaments may be responsible for this 
finding. 
More recent investigations prove that interleukin-6 (IL-6), modulates several physiol-
ogic functions and can serve as a marker of disease severity in experimental murine 
sepsis induced by cecal ligation and puncture.61,62 Studies of Leon et al. showed that 
TNF-α concentrations are related to lethality in mice.63 Turnbull et al. were able to 
identify a threshold value of IL-6 of 14,000 pg/mL, 6 h after start of sepsis, predict-
ing a mortality of 100% irrespective of antibiotic treatment in mice.64 So both TNF-α 
and IL-6 may be regarded as key mediators and parameters of murine sepsis sever-
ity. 
2.8 Human studies 
Antibiotic induced endotoxin release 
Several authors demonstrated antibiotic-induced endotoxin liberation during treat-
ment of human sepsis.47,65 One of the first reports published, concerned neonates 
with Gram-negative meningitis. In those patients, significantly higher endotoxin 
concentrations were shown in cerebrospinal fluid after local administration of gen-
tamicin. This was associated with higher concentrations of local IL-1ß and a poor 
clinical outcome compared with patients receiving parenteral antibiotic therapy 
only.31 In a study in neonates with sepsis and necrotizing enterocolitis, endotoxemia 
turned out to be an important contributor to multi-organ failure and mortality.66 In 
contrast, in a prospective study in septic patients, only 3 out of 20 patients showed 
an increase of plasma endotoxin concentrations during treatment.67 In a different 
study in 18 sepsis patients, stable values of circulating endotoxin and declining IL-1, 
IL-6 and IL-8 were observed during the first 4 h of treatment.68 
Cytokines and outcome 
In a prospective study of 97 sepsis patients, IL-6 concentrations were 69% higher in 
patients who died of sepsis, compared with survivors.69 This is in line with the sepsis 
study mentioned earlier, in which plasma concentrations of TNF-α and IL-6 signifi-
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cantly rose and correlated with disease severity.66 A very recent study also showed a 
significant association between circulating IL-1ß, TNF-α and IL-6 and mortality.68 In 
contrast, other investigators observed that high serum TNF-α concentrations in 
patients with abdominal sepsis was associated with increased survival,70 whereas 
persisting high levels of circulating IL-6 were associated with mortality.71 
Studies comparing antibiotics 
Several studies have been performed comparing imipenem, with affinity for PBP-1/-
2, and ceftazidime (PBP-3), mostly in patients with infections of the urinary tract. 
Imipenem treatment turned out to be associated with lower endotoxin concentra-
tions in blood and urine than ceftazidime treatment in one study.72 However, this 
finding could not be confirmed in a subsequent study comparing imipenem and 
ceftazidime in patients with urinary tract infections, in which no differences of plasma 
or urine endotoxin, IL-6, IL-8 or TNF-α concentrations were found between groups 
within the first 8 h after antibiotic administration.73 More recently, a comparative 
study of cefuroxime, netilmicin and ciprofloxacin, performed in 74 patients with acute 
pyelonefritis, also failed to show relevant differences of LPS and TNF-α in serum.74 In 
a different study, significantly lower serum TNF-α and IL-6 concentrations were 
encountered in patients treated with ciprofloxacin, compared with ceftazidime, 
without any difference in final outcome.75 
In a study comparing ceftazidime and imipenem treatment in 27 patients with 
various Gram-negative infections, antibiotic-induced endotoxin release was detect-
able, with concomitant significant increases of plasma IL-6 and TNF-α, without 
differences between both antibiotics.76 
Melioidosis is an infectious disease, caused by Burkholderia pseudomallei, a Gram-
negative microorganism endemic in Southeast Asia and Australia. In a study of 
severe melioidosis with acute septicaemia, ceftazidime-treated patients (n=34) 
showed higher systemic endotoxin concentrations after the first antibiotic dose, 
compared with patients treated with imipenem (n=34), but this difference did not 
affect survival.77 In a clinical study concerning Gram-negative nosocomial pneumo-
nia, significant elevated plasma concentrations of LPS, IL-6, and TNF-α were encoun-
tered in patients (N=24); however, again without differences between ceftazidime- 
or imipenem-treated patients.78 
2.9 Conclusion 
Antibiotic-induced endotoxin release during treatment of severe infections has been 
an intriguing subject of research in the last 20 years. In-vitro studies convincingly 
demonstrated that antibiotic type and dose influence bacterial morphological re-
sponses and subsequent endotoxin liberation. Further studies suggest that these 
effects might alter the hosts cytokine responses and could change the clinical out-
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come. However, especially results of in-vivo studies still remain variable and contra-
dictory, which is obviously at least partly explained by the multitide of factors influ-
encing the performance of those studies (Table 1.). Until recently, the exact dose 
and dosing-schedule relationship of filament induction and the extent to which the 
in-vitro observations can be extrapolated to in-vivo infections remained unclear. The 
present thesis aims at providing more clarity on the clinical relevance of antibiotic-
induced morphological changes and possibilities to influence this phenomenon by 
adjustments of doses or schedules of antibiotic treatment. 
 
 
Table 1. Sources of outcome variability in murine and human sepsis research. 
HOST BACTERIA ENDOTOXIN ANTIBIOTIC STUDY DESIGN 
Type (human, 
animal) 
Family, genus, 
strain 
Type Class Selection biass host 
Age Growth phase Binding to plasma 
factors 
PBP-affinity Selection biass 
infection type 
Sex Inoculum effect Ratio free/total 
endotoxin 
Dose Number of subjects, 
power of study 
Focus of infection Post-antibiotic effect Assay Regimen Randomization, 
blinding, controlling 
Stage of infection Localization of 
infection 
Kinetics, clearance Combination therapy Duration of study 
Comorbidity, 
comedication 
Resistance factors  Pharmacokinetics, 
pharmacodynamics 
Definition of terms 
(sepsis, shock, 
infection) 
Pharmacokinetic and 
pharmacodynamic 
parameters 
  Moment of initiation 
of therapy 
Definition of end-
points 
Pretreatment with 
antibiotics 
   Inter- and intra-assay 
variability concerning 
bacteria, cytokines 
and antibiotics 
    Rigidness of inclusion 
and exclusion criteria 
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Introduction 
In-vitro studies have shown endotoxin release when Gram-negative bacteria are 
exposed to antibiotics.1-3 Direct evidence that antibiotic therapy can promote en-
dotoxin release in-vivo has been provided by studies in rabbits infected experimen-
tally with Escherichia coli.4,5 Rokke et al. demonstrated that endotoxin is liberated 
during antibiotic treatment with gentamicin in an experimental porcine septicemia 
model, and that this release negatively correlates with cardiac performance.6 Also, 
the role of antibiotic-induced endotoxin as a toxic factor during treatment of Neisse-
ria meningitidis infection has been described.7 Shenep et al. demonstrated antibiotic-
induced endotoxin liberation during treatment of human septicemia,8 as well as 
McCartney et al. who also described some patients with rising endotoxin levels during 
the treatment of septic shock, in response to antibiotic therapy.9 Mustafa et al. 
demonstrated increased endotoxin and IL-ß levels in cerebrospinal fluid of infants 
with meningitis caused by Gram-negative bacilli, which seemed to be associated with 
intraventricular gentamicin therapy.10 These patients had a poor outcome compared 
with infants who received parenteral antibiotic therapy only. 
So far, the endotoxin liberating effect of penicillin,9 moxalactam,8 cefotaxime,5 the 
aminoglycosides kanamycin11 and gentamicin,4,6,10 several quinolones1,3 and chloram-
phenicol4,5 have been studied. 
In a previous study,12 we examined antibiotic-induced release of endotoxin from E. 
coli using a variety of antibiotics, including several ß-lactam antibiotics and an 
aminoglycoside in-vitro. The lowest release of free endotoxin was encountered 
during imipenem-treatment and the combination of imipenem/tobramycin. This 
slightly increased release of free endotoxin during imipenem exposure occurred 
mainly within the first hour. This finding suggested a rapid lysis of bacteria by this 
bactericidal antibiotic, associated with a quick liberation of the relatively low amount 
of endotoxin molecules present at the start of treatment. Ceftazidime, on the other 
hand, is less bactericidal but, nevertheless, caused a 20-fold increase of free en-
dotoxin in these studies. Control cultures without antibiotics liberated 3-fold higher 
amounts of free endotoxin compared with imipenem or imipenem/tobramycin, 
suggesting that treatment with certain highly lytic bactericidal antibiotics do not 
necessarily lead to high antibiotic-induced endotoxin releases. Generally, the quantity 
of liberated endotoxin corresponds to the numbers of killed cfu. In the case of 
isolates treated with cefuroxime or aztreonam, the magnitude of the increase in free 
endotoxin was inordinately high (117- and 222-fold, respectively) compared with 
imipenem-treated cultures. Microscopic judgement of those cefuroxime- or aztreo-
nam-treated bacterial isolates showed an increased cell mass with large filamentous 
forms. So these studies showed that induction of filaments may somehow play a role 
in the bacterial capacity of enhanced antibiotic-induced free endotoxin releases. 
In another study, the influence of antibiotic-induced endotoxin released by E. coli 
isolates on the production of tumour necrosis factor-α (TNF-α) by human monocytes 
was investigated.13 After 4 h of incubation, all high-dose antibiotic treated cultures 
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induced a similar initial rise of extracellular TNF-α concentrations, irrespective of the 
antibiotic applied. However, after 24 h of incubation, a dramatic further rise of TNF-α 
production was noticed in cefuroxime- or aztreonam-treated cultures, compared with 
(high dose) ceftazidime- or imipenem-treated cultures. TNF-α production induced by 
filtrates of cefuroxime treated cultures could be reduced by simultaneous administra-
tion of tobramycin. It was established that filament-inducing antibiotics not only 
induced higher levels of endotoxin, but culture filtrates also provoked an excessive 
production of TNF-α. For aztreonam and imipenem this endotoxin- and TNF-α pro-
duction was not dose-dependent. However, for both cefuroxime- and ceftazidime- 
treated cultures, low dose treatment resulted in significant higher TNF-α productions. 
This concentration dependency of TNF-α production by cefuroxime- or ceftazidime- 
exposed isolates could be explained by inhibition of penicillin binding protein (PBP)-1 
by high antibiotic concentrations, leading to a rapid cell-lysis of bacteria, while 
exposure to lower concentrations mainly resulted in PBP-3 inhibition, causing forma-
tion of massive filaments. Aztreonam has a non-dose dependent high affinity for 
PBP-3 and a very low affinity for PBP-1, which explains that both high and low 
aztreonam concentrations induced filamentous bacteria and equivalent increases of 
endotoxin- and TNF-α releases. Imipenem has a high affinity for PBP-2. During 
exposure to both high and low concentrations of imipenem spheroplast formation 
occurred, irrespective of the concentration applied. Presence of spheroplasts resulted 
in relatively low concentrations of both endotoxin and TNF-α production under all 
circumstances. 
So this study showed a direct correlation between bacterial morphology, antibiotic-
induced endotoxin contents and the production of extracellular and cell-associated 
TNF-α in-vitro. 
 
To investigate whether these findings can be of importance when choices of antibi-
otic regimens are made, the present in-vitro studies were aimed at the release of 
endotoxin from Escherichia coli and Pseudomonas aeruginosa isolates, applying 
various concentrations of continuous and intermittent dosing schedules of several 
antibiotics with different PBP-affinities. 
Materials and methods 
Microorganisms 
Isolates of E. coli (ATCC 25922) and P. aeruginosa (ATCC 27853) were used. Bacte-
ria were stored at -70°C and subcultured on blood agar on day -1. Subsequently, two 
colonies were inoculated in 5 mL brain heart infusion (BHI) broth (Difco Laboratories 
Inc., Detroit, MI, USA) and incubated overnight at 37°C. MICs for E. coli were: 
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ceftazidime 0.25 mg/L, aztreonam 0.125 mg/L, imipenem 0.125 mg/L. MICs for P. 
aeruginosa were: ceftazidime 1 mg/L, imipenem 1 mg/L. 
Antibiotics 
For the E. coli study, ceftazidime (Glaxo, Nieuwegein, The Netherlands), imipenem 
(Merck, Sharp & Dome , Haarlem, The Netherlands) and aztreonam (Squibb, Rijswijk, 
The Netherlands) were used at concentrations of 4 x, 40 x and 400 x MIC in BHI 
broth, during 4 h. Measurements were performed in triplicate. Continuous concentra-
tion levels were applied by replacing 2 mL of the initial 8 mL antibiotic-containing 
broth by 2 mL of fresh antibiotic solution in BHI-broth every 30 min. Experiments 
with declining antibiotic concentrations were performed by replacement of 2 mL of 
the test solutions with antibiotic-free BHI-broth every 30 min. 
P. aeruginosa studies were conducted with ceftazidime and imipenem at doses of 4 x 
and 40 x MIC during an 8 h period. Continuous or declining antibiotic concentrations 
were applied as described above. Cultures, antibiotic-containing and antibiotic-free 
BHI-broth were stored in a water bath at 37°C during the study period. 
Endotoxin assay 
Endotoxin concentrations were determined using the chromogenic Limulus amoebo-
cyte lysate assay (LAL, KabiVitrum, Amsterdam, The Netherlands) according to the 
prescriptions of the manufacturer.12 The detection limit of the assay was 0.05 EU/mL. 
Samples for endotoxin measurements were obtained at t = 0, and at t = 1, 2 and 4 h 
in the E. coli study and at t = 2, 4 and 8 h in the P. aeruginosa study. For determina-
tion of free endotoxin concentrations, 0.5 mL of the sample was passed through a 
0.45 μm pyrogen-free filter (Millipore, Amsterdam, The Netherlands) and stored in 
pyrogen-free Falcon tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Samples 
were immediately stored at -70°C, until assays were performed. 
Viable counts 
At t = 0, 1, 2, 4 and 8 h, 20 μL of control and test cultures were removed and diluted 
10-fold serially in 180 μL BHI-broth on microtitre plates for performance of colony 
counts. After overnight incubation on blood agar plates, colony counts (colony 
forming units, cfu) were performed. 
Statistical analysis 
Data were analysed by one-way analysis of variance using the SPSS/PC+ statistical 
package. Statistical tests were considered significant at p< 0.05. 
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Results 
E. coli study 
Viable counts 
The inoculum of E. coli at the start of the experiment was approximately 1 x 106 
cfu/mL. Applying antibiotics at 400 x, 40 x or 4 x MIC, viable counts were signifi-
cantly ( 2-3 log) lower at t = 4 h compared to controls, without differences between 
antibiotic types or dosing regimen. During continuous aztreonam and imipenem 
treatments, the most rapid decline of viable counts was observed. 
Endotoxin 
 
 
Figure 1. Antibiotic-(400 x MIC) induced release of free endotoxin in E. coli isolates exposed to continuous or 
declining concentrations of various antibiotics with different PBP-affinities 
 
 
At 400 x MIC, aztreonam-treated cultures showed significant (p <0.05) higher total 
endotoxin concentrations (19 fold) at t = 4 h, compared with imipenem and cef-
tazidime. Total endotoxin levels in controls and aztreonam-treated cultures did not 
differ at t = 4 h.  
High amounts of free endotoxin concentrations were observed during initial treat-
ment with ceftazidime and imipenem (1 to 2 h), declining to low levels at t = 4 h (Fig 
1.) Aztreonam treatment resulted in a delayed, but higher peak of free endotoxin at t 
= 4 h (Fig 1.), compared to ceftazidime-exposed, imipenem-exposed and control 
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cultures. No differences were observed between continuous or intermittent dosing 
schedules.  
 
 
Figure 2. Antibiotic-(40 x MIC) induced total endotoxin contents of E. coli isolates, exposed to continuous or 
declining concentrations of various antibiotics with different PBP-affinities 
 
 
At a concentration level of 40 x MIC, imipenem exposure resulted in significant (p < 
0.05) lower contents of total endotoxin at t = 4 h compared to controls, aztreonam 
and ceftazidime treated cultures, irrepective of the dosing regimen (Fig 2.). Exposure 
to ceftazidime resulted also in a significant higher release of free endotoxin com-
pared with imipenem in both dosing regimens (Fig 2. and 3.). A continuous cef-
tazidime at 40x MIC caused a significant reduction (50%, p <0.05) of the amount of 
total endotoxin, compared with declining concentrations of ceftazidime 40 x MIC (Fig 
2.). Comparable to previous studies,12,13 no differences between endotoxin concen-
trations were observed during continuous or intermittent dosing schedules of either 
aztreonam or imipenem. 
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Figure 3. Antibiotic-(40 x MIC) induced release of free endotoxin in E. coli isolates exposed to continuous or 
declining concentrations of various antibiotics with different PBP-affinity  
 
 
At low continuous ceftazidime concentrations (4 x MIC), microscopic judgement of 
cultures showed massive filament formation. LAL-assays showed significant higher 
levels of total endotoxin, compared to 40 x MIC or 400 x MIC ceftazidime-exposed 
cultures. This finding suggests an inverse relationship between concentrations of 
continuous ceftazidime and the extent of filamentation and endotoxin concentrations 
(Fig 4.). 
 
 
Figure 4. Dose dependent total endotoxin concentrations in E.coli isolates during continuous ceftazidime 
incubation 
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Pseudomonas aeruginosa study 
Viable counts 
Baseline concentrations of Pseudomonas isolates were 3 x 106 cfu/mL. Ceftazidime at 
a concentration of 50 x MIC caused a significant 2 log decline of viable counts during 
the 8 h incubation period, without significant differences between dosing schedules. 
Imipenem treatment showed no detectable viable counts at t = 8 h during both 
dosing schedules. Gram’s stains revealed bacterial debris and only a few spherical 
cells. At a dose of 5 x MIC, cfu counts remained stable during exposure to continu-
ous or declining concentrations of ceftazidime, reflecting bacteriostatic growth. 
Exposure to both imipenem regimens resulted in significant lower cfu counts (2 log) 
of Pseudomonas t = 8 h, compared to the initial cfu concentrations.  
Endotoxin 
Ceftazidime exposure at 50 x MIC (Fig 5.) resulted in an 8-fold higher level of free 
endotoxin, compared with equivalent concentrations of imipenem. Compared with 
controls, free endotoxin was 3-fold higher (p <0.05) in ceftazidime-exposed cultures. 
Differences between both dosing regimens were not significant. During exposure to 
imipenem the percentage of free endotoxin in relation to total endotoxin rose to 60% 
already at t = 2 h until t = 8 h. The percentage of free endotoxin in controls was 
15% during the whole 8 h period, while ceftazidime treatment resulted in 20% free 
endotoxin at t = 4 h, which increased to 50% at t = 8 h. 
 
 
 
Figure 5. Free endotoxin concentrations in Pseudomonas isolates during incubation with various antibiotics 
(50 x MIC)  
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Figure 6. Free endotoxin concentrations in Pseudomonas isolates during incubation with various antibiotics  
(5 x MIC) 
 
 
In isolates of Pseudomonas exposed to a concentration of 5 x MIC (Fig 6.), imipenem 
showed the same pattern described above and again, ceftazidime induced significant 
higher contents of endotoxin at t = 8 h. Ceftazidime induced a low concentration of 
free endotoxin at t = 8 h, reflecting only 12.5% of the amount produced in the 50 x 
MIC experiment, and 33% of the amount of free endotoxin produced by controls. In 
5 x MIC ceftazidime-exposed isolates, the percentage of free endotoxin in relation to 
total endotoxin stayed under 20% during the whole experiment. Studies of Gram’s 
stains of these isolates revealed massive filament formation, so enhancement of cell-
mass, without significant lysis of filaments is assumed. 
Discussion 
Different effects on endotoxin release by ß-lactam antibiotics can be explained by 
binding to and inhibition of various penicillin binding proteins (PBPs).14 The three 
penicillin-binding proteins of E. coli essential for antibacterial treatment are referred 
to as PBP-1, PBP-2 and PBP-3. 
The extent of filamentation and the propensities of ß-lactam antibiotics to induce 
release of endotoxin is antibiotic concentration dependent and is influenced by the 
relative affinities of the antibiotics for PBP-1, PBP-2 or PBP-3.15 Wientjes and Nan-
ninga16 showed that the PBP-3/-2 and PBP-3/-1 inhibition ratios influence the length 
of bacteria and the amount of newly synthesized endotoxin. Jackson and Kropp15 
reported a correlation between subMIC and MIC levels of antibiotics and induction of 
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filaments, combined with high endotoxin releases in the absence of significant 
bacterial lysis. 
 
Inhibition of PBP-1 is associated with rapid killing and lysis, whereas inhibition of 
PBP-2 induces the formation of spherical cells and inhibition of PBP-3 induces fila-
ment formation.14,17 Since most antibiotics bind to more than one PBP, morphology 
associated with ß-lactam binding to Gram-negative bacteria depends on the net sum 
of the individual inhibitory effects. The effects of cefuroxime and aztreonam, i.e. the 
formation of long filamentous structures during the first hours of treatment, are the 
result of PBP-3-inhibition. At low doses (<5 mg/L), ceftazidime and (to a lesser 
extent) cefuroxime bind primarily to PBP-3, but at higher concentrations these 
antibiotics also inhibit PBP-1.14,18 This binding pattern explains why long E. coli 
filaments are observed at lower doses of ceftazidime, and rapid cell lysis occurs when 
high doses of ceftazidime are applied.12,13 Using Pseudomonas isolates, a high dose 
of ceftazidime did not cause rapid cell-lysis in our studies, but rather induced fila-
ment formation, suggesting a predominant binding to PBP-3, despite of a concentra-
tion of 50 mg/L (50 x MIC) for that particular strain. 
Imipenem has been reported to bind predominantly to PBP-2. So treatment with this 
drug can result in formation of spheroplasts. Additionally, very rapid cell lysis, as 
suggested by the presence of only a few spherical cells, also suggests inhibition of 
PBP-1 in case of the 50 mg/L (50 x MIC) level used in the Pseudomonas study. 
The early rise of free endotoxin observed during exposure of E. coli to high dose 
ceftazidime or imipenem and during exposure of Pseudomonas isolates to imipenem 
aim at a rapid and effective lysis of bacteria by these antibiotics.  
Not only the choice of antibiotic type and concentration level is important. The 
studies presented in this paper reveal convincingly that the dosing schedule is 
relevant also, as a constant ceftazidime concentration at 40x MIC induced 50% lower 
contents of total endotoxin in E. coli, isolates, compared with isolates exposed to 
decling concentrations of ceftazidime. This observation is attributable to more exten-
sive filament formation when ceftazidime concentrations decline. The high/low dose 
studies mentioned in the introduction of this paper correlate quite well with these 
results.12 
The higher concentration of free endotoxin associated with filament-inducing antibi-
otics, aims at augmentation of cell-mass and concomitant augmentation of endotoxin 
content before lysis. Observations with filament-inducing antibiotics show that a 
correlation between cfu counts and the amount of free endotoxin is absent in those 
cases, suggesting that cfu counts may not be an appropriate parameter of cell mass 
in case of filamentation.  
The data of the present paper support the hypothesis that a reduction of bacterial 
cell-mass either by choosing the appropriate antibiotic type, dosing regimen, concen-
tration or combination of antibiotics may be of clinical importance during initial 
treatment of severe Gram-negative infections. 
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Introduction 
Carbapenems, like other antibiotics of the ß-lactam-group, induce morphological 
changes in Gram-negative bacteria by binding to and inhibition of Penicillin-Binding 
Proteins (PBPs). PBPs, which are located in the bacterial cytoplasmic membrane, are 
important during growth and morphogenesis of bacteria. Inhibition of PBP-2 leads to 
transformation of rods into large rounded bacteria, called spheroplasts. PBP-3-
inhibition causes formation of long filamentous bacteria by the inability of bacteria to 
septate after multiplication of their cell-mass. The latter morphological change is 
associated with a fast decline of the amount of colony forming units, as one filament, 
despite of a large cell-mass, is counted as only one colony forming unit (cfu). These 
filaments contain high amounts of endotoxin-molecules (lipopolysaccharide, LPS) in 
their cell wall, and are therefore potentially more toxic to the host.1,2 
Meropenem has affinity for both PBP-2 and PBP-3 in Gram-negative bacteria and 
may thus induce both spheroplast as well as filament formation.3 Studies on this 
subject are scarce and mostly limited to only a small number of dose levels. The 
present study was aimed at expanding our knowledge on the effects of meropenem 
on bacterial morphology, at various concentrations. 
Objectives 
We studied morphological changes of Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella pneumoniae at various concentrations and during longer periods of incuba-
tion with meropenem, to check bacterial filament or spheroplast formation. We also 
made cfu counts of E. coli during incubation at various concentrations of mero-
penem. 
Materials and methods 
Overnight cultures of E. coli ATCC 25922, P. aeruginosa ATCC 27853 and K. pneu-
moniae ATCC 43816 were exposed to 9 concentrations of meropenem, of which at 
least 5 MIC or sub-MIC concentrations. In a control-experiment, E. coli bacilli were 
exposed to saline or ceftazidime 0.125 mg/L (0.5 x MIC) to verify normal growth and 
the ability of induction of antibiotic-induced filament formation in this experimental 
setting, respectively. 
MICs for meropenem were 0.025 mg/L, 1 mg/L and 0.03 mg/L for E. coli, P. aerugi-
nosa and K. pneumoniae, respectively. Test concentrations of meropenem were 
0.0016 mg/L, 0.0032 mg/L, 0.00625 mg/L, 0.0125 mg/L, 0.025 mg/L, 0.05 mg/L, 0.1 
mg/L, 1 mg/L, and 5 mg/L. 
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Cfu counts were performed at t = 0, 1, 2½ and 4 h. At t = 0, 2, 4, 8, and 24 h speci-
men were taken for Gram’s stains. 
Results 
In Fig 1. growth curves of E. coli during 4 h of incubation at MIC and subMIC levels 
(0.025-0.0016 mg/L) are shown. 
 
 
 
Figure 1. Growth and kill-curves of E. coli during exposure to various concentrations of meropenem 
 
 
Controls, exposed to saline, showed only rod-shaped bacilli. The lowest concentra-
tions of meropenem did not induce a decline of colony forming units, despite the 
presence of obvious morphological changes. 
Different forms of spheroplasts were shown at all time points during exposure to all 
concentrations of meropenem in E. coli, P. aeruginosa and K. pneumoniae: large and 
small, with and without irregularities on their cell surface (Fig 2A.). At all dose-levels, 
we were not able to induce filaments in the three strains tested. Control cultures 
exposed to ceftazidime, showed large filaments at t = 2, 4, 8 and 24 h (Fig 2B.). 
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Figure 2.  
A. Spheroplasts of E. coli after exposure to meropenem 0.5 x MIC 
B. Filaments of E. coli after exposure to ceftazidime 0.5 x MIC 
Full colour illustration on page 131 
Discussion 
In spite of the proven dual binding properties of meropenem to both PBP-2 and PBP-
3, no filament formation was demonstrated in this in-vitro experiment, even at very 
low dose-levels of meropenem. As during filament formation cfu rapidly decline, this 
morphological finding explains the absence of fast decline in cfu during the first 
hours of incubation. 
Apparently, the affinity of meropenem for both receptors differs, in favour of PBP-2. 
This is in line with the findings of Yang et al.4 and Trautman.5 Other investigators 
showed a dose dependency of morphological changes during meropenem exposure 
in P. aeruginosa: at sub-MIC dose levels filaments were shown, whereas at concen-
trations of 2 x MIC and higher spheroplasts were shown.6 In our P. aeruginosa strain 
we could not confirm this finding. 
During longer incubation-periods, up to 24 h, viable spheroplasts were still present. 
So it has to be taken into account that those morphologically altered bacteria can still 
be pathogenic. 
The inability of meropenem to induce bacterial filament formation, at least in some 
Gram-negative strains, may be an advantage in the initial treatment of sepsis, 
because spheroplasts contain less endotoxin in their cell wall and will be probably be 
less pathogenic to the host, compared with bacterial filaments induced as can be 
induced by other ß-lactams, like ceftazidime, cefotaxime or aztreonam.2,7 
   A B
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Abstract 
Ceftazidime and cefotaxime are ß-lactam antibiotics with dose-related affinities for 
penicillin-binding protein(PBP)-3 and PBP-1. At low concentrations, these antibiotics 
inhibit PBP-3, leading to filament formation. Filaments are long strands of non-
dividing bacteria that contain enhanced quantities of endotoxin molecules. Higher 
concentrations of ceftazidime or cefotaxime cause inhibition of PBP-1, resulting in 
rapid bacterial lysis, which is associated with low endotoxin release. In the present 
study, 37 isolates of Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa and 
Acinetobacter spp. were studied over a 4-h incubation period in the presence of eight 
concentrations of ceftazidime or cefotaxime. As resistance of Gram-negative bacteria 
is an emerging problem in clinical practice, 14 isolates of E. coli and Klebsiella pneu-
moniae that produced extended-spectrum ß-lactamases (ESBLs) were also investi-
gated. 
Morphological changes after exposure to the ß-lactam antibiotics revealed recognis-
able patterns in various bacterial families, genera and isolates. In general, all isolates 
of Enterobacteriaceae produced filaments within a relatively small concentration 
range, with similar patterns for E. coli and K. pneumoniae. Pseudomonas and Acine-
tobacter spp. produced filaments in the presence of clinically relevant concentrations 
of both antibiotics as high as 50 mg/L. In all genera, filament-inducing capacity was 
clearly related to the MIC. Ceftazidime induced filament production in more isolates 
and over wider concentration ranges than did cefotaxime. Interestingly, ESBL-
producing isolates were not protected against filament induction. The induction of 
filament production may lead to additional risks during empirical treatment of severe 
infections. 
Introduction 
ß-lactam antibiotics act by inhibiting the penicillin-binding-proteins (PBPs) anchored 
in the cytoplasmic membrane of Gram-negative bacteria.1 Each PBP has a specific 
role in bacterial proliferation and maintenance of morphology. Blocking of PBP-1 
leads to rapid bacterial lysis, with rapid release of relatively small amounts of en-
dotoxin.2 Binding of ß-lactam agents to PBP-3 results in the formation of filaments, 
caused by the inability of bacteria to septate after doubling of their cell mass. Fila-
ments are long strands of non-dividing bacteria that contain enhanced quantities of 
endotoxin.2,3 The mechanism by which the endotoxin content is enhanced of is still 
unclear.4,5 Endotoxin, or lipopolysaccharide, is known be a key mediator in Gram-
negative bacterial infections,6-10 and the high endotoxin content of filaments means 
that there is a risk of delayed, but higher, release of endotoxin during ongoing 
antibiotic treatment of infections.10-16 Each ß-lactam agent has a specific binding 
affinity for different PBPs. Ceftazidime and cefotaxime, which are oxyimino-
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containing cephalosporins, both bind to PBP-3 at relatively low concentrations, and to 
PBP-1 at higher concentrations.2,17,18 Reports concerning the concentrations at which 
specific PBP-binding occurs are scarce.19 Previous studies have revealed that fila-
ment-inducing concentrations of ceftazidime vary, from concentrations around the 
MIC for Escherichia coli to concentrations >50 x MIC for P. aeruginosa.2,20 
Resistance to ß-lactam antibiotics is a major problem in clinical medicine. This 
problem is typically caused by the acquisition of plasmids carrying ß-lactamase-
encoding genes, including those that encode extended-spectrum ß-lactamases 
(ESBLs). ESBL-producing Klebsiella pneumoniae and E. coli strains are now relatively 
common in healthcare settings throughout the world.21-26 ESBLs are capable of 
efficiently hydrolysing penicillins, narrow-spectrum cephalosporins, many extended-
spectrum cephalosporins, the oxyimino cephalosporins, and the monobactams.27,28 In 
addition to non-susceptibility, filament induction may add the risk of accumulation of 
large amounts of bacterial lipopolysaccharide during initial empirical antibiotic ther-
apy, when culture and MIC data are not yet available. 
The aim of the present study was to determine the concentrations of ceftazidime and 
cefotaxime at which PBP-inhibitory effects change, and to relate this to cfu counts 
and MICs. The study also investigated whether these antibiotics are capable of 
filament production in ESBL-producing isolates of Enterobacteriaceae. It was hy-
pothesised that filament induction may be absent or occur only at higher antibiotic 
concentrations, in such isolates following total or partial inactivation of antibiotics 
before binding to PBP-3. 
Materials and methods 
Bacteria 
In total, 37 isolates of Gram-negative bacteria, collected mainly during routine daily 
practice in the microbiological laboratory of the Atrium Medical Centre (Heerlen, The 
Netherlands) were used for this study. The isolates were identified using the VITEK 2 
system (bioMérieux, Durham, NC, USA)29 and MICs were confirmed by Etests (AB 
Biodisk, Solna, Sweden). E. coli, K. pneumoniae, Klebsiella oxytoca, P. aeruginosa, 
Acinetobacter baumannii and other Acinetobacter spp. with varying degrees of 
insusceptibility for cefotaxime and ceftazidime were tested. Seven known ESBL-
producing isolates of E. coli , seven known ESBL-producing isolates of K. pneumoniae 
and three standard reference strains (E. coli ATCC 25922, P. aeruginosa ATCC 27853 
and K. pneumoniae ATCC 43816) were also included in the study. 
Antibiotics 
Ceftazidime (GlaxoSmithKline, Zeist, The Netherlands) and cefotaxime (Aventis 
Pharma, Hoevelaken, The Netherlands) were used at eight concentrations: 0.1, 1, 5, 
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10, 20, 30, 40 and 50 mg/L. Each experiment also contained a negative control (no 
antibiotic) to serve as a reference for bacterial cell length. 
Bacterial counts 
The relationship between filament formation and cfu was determined in an experi-
ment using E. coli ATCC 25922 grown in broth in the presence of ceftazidime or 
cefotaxime at concentrations of 0, 0.1, 1.0, 5.0, 10, 20, 30, 40, 50 mg/L. After 
incubation for 4 h, samples were plated on blood agar using a spiral plater (Whitley 
Automatic Spiral Plater; Don Whitley Scientific, Shipley, UK). After overnight incuba-
tion, colonies were counted, with a detection limit of 4 x 103 cfu/mL. This experiment 
was performed in triplicate. 
Antibiotic exposure studies 
One day before each experiment, two bacterial colonies were suspended in tryptose 
phosphate broth and incubated overnight to obtain cultures containing c. 108 cfu/mL. 
Shortly before the start each experiment, a standard solution of antibiotic was diluted 
in sterile saline to achieve the desired concentrations, and 20 μL of each antibiotic 
dilution was added to the wells of a microtitre plate. Subsequently, 180 μL of bacte-
rial suspension were added, mixed thoroughly, incubated at 37°C for 4 h, and then 
examined by light microscopy following Gram’s stain. 
Morphology 
Following Gram’s stain, cultures were assessed by two investigators using light 
microscopy at magnifications of x 250, x 400 and x 1000. Filaments were classified 
as short (+) if they had a length of three to ten bacterial cells, and as long (++) if a 
length of ten or more bacterial cells was observed. The two assessors were unaware 
of the identification and MIC for each isolate. 
Statistical analysis 
Statistical analysis was performed using SPSS v.10.0 for Windows (SPSS Inc., Chi-
cago, IL, USA) and GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, CA, 
USA). Differences in filament-inducing concentrations were analysed by multivariate 
analysis (ANOVA) for normally distributed parameters, followed, when appropriate, 
by post-hoc t-tests. Parameters without a normal distribution were analysed using 
the non-parametric Kruskal-Wallis test, followed by the Mann-Whitney test to investi-
gate differences among groups. Correlations among parameters with a normal 
distribution were determined using Pearson’s correlation test. For non-normally 
distributed parameters, Spearman’s rank correlation test was applied. Statistical tests 
were considered significant at p<0.05. 
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Results 
Cfu counts 
Fig 1. shows the viable counts of E. coli ATCC 25922 following exposure to eight 
concentrations of ceftazidime or cefotaxime for 4 h. At the start of the experiments, 
the viable counts were 4 x 107 cfu/mL, with untreated controls showing an increase 
to 1 x 108 cfu/mL after 4 h. All antibiotic-treated cultures showed lower cfus after 4 h 
when compared with controls, including cultures exposed to concentrations at or 
below the MIC (0.19 mg/L for ceftazidime, 0.064 mg/L for cefotaxime). Examination 
of Gram’s stains of the cultures confirmed the formation of filaments at ceftazidime 
0.1-10 mg/L and cefotaxime 0.1-1 mg/L (Table 1. and 2.). 
 
 
 
Figure 1. Cfu counts after 4 h incubation of E. coli ATCC 25922 at various concentrations of ceftazidime or 
cefotaxime 
 
 
Morphological studies 
Morphological studies revealed that filaments were shorter at the lowest and the 
highest filament-inducing concentrations than in the middle of the filament-inducing 
concentration ranges (Fig 2., Table 1. and 2.). In contrast to E. coli, P. aeruginosa 
and Acinetobacter, all of which showed long filaments at certain concentrations, 
Klebsiella showed short filaments only. 
Seven isolates, including six ESBL-producing isolates with high MICs, did not form 
filaments in this experiment. Also, one isolate of K. pneumoniae (Kpn 3, Table 1. and 
2.) with very low ceftazidime and cefotaxime MICs (0.032 and 0.016 mg/L, respec-
tively) did not show filamentous forms at any concentration tested. 
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Figure 2. Rods, short and long filaments (1000 x) of E. coli, P. aeruginosa, K. pneumoniae and A. baumanii 
Full colour illustration on page 132 
 
Exposure studies using ESBL-negative isolates 
When bacterial families are compared, Enterobacteriaceae had significantly lower 
maximum filament-inducing concentrations of ceftazidime, with a mean of 11.11 
mg/L (SD 7.7) compared with 46.7 mg/L (SD 8.2) for Pseudomonas spp. and 34.2 
mg/L (SD 22.7) for Acinetobacter spp. (p 0.0001 and 0.007, respectively). For 
cefotaxime, the same pattern was found (p 0.0001) (Table 1. and 2.). 
Relative filament-inducing concentrations of ceftazidime were higher for Enterobacte-
riaceae (mean ratio 47.3 x MIC, SD 20.0) and Pseudomonas spp. (mean ratio 55.3 x 
MIC, SD 39.0), than for Acinetobacter spp. (mean 14.0 x MIC, SD 12.0)(p 0.004 and 
0.05, respectively). For cefotaxime, the ratios were 36.9 x MIC (SD 50.0), 2.7 x MIC 
(SD 2.0), 5.1 x MIC (SD 4.6), respectively. Again, the differences between Entero-
bacteriaceae and the other groups were significant (p 0.003 and 0.019, respectively). 
E. coli
K. pneumoniae
P. aeruginosa
A. baumanii
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For cefotaxime, there was also a significant difference in the lowest filament-inducing 
concentration for Enterobacteriaceae (0.264 mg/L, SD 0.369) and either Pseudomo-
nas spp. (9.2 mg/L, SD 10.2) or Acinetobacter spp. (3.2 mg/L, SD 2.5) (p 0.009 and 
0.001, respectively). 
Comparing different Enterobacteriaceae, similar patterns were found for E. coli and 
Klebsiella spp. for all values and both antibiotics. Within the genus Klebsiella, there 
were differences among isolates, with filaments being induced at higher concentra-
tions in K. oxytoca than in K. pneumoniae (p 0.046 and p 0.018 for ceftazidime and 
cefotaxime, respectively). 
Exposure studies using ESBL-positive isolates 
Filament production was induced in eight of 14 ESBL-positive isolates, and by cefo-
taxime in four ESBL-positive isolates. A clear relationship between MIC and filament 
induction was revealed in ESBL-positive isolates as, without exception, the MICs for 
filament-producing ESBL-positive isolates were ≤12 mg/L). 
When ESBL-positive and ESBL-negative isolates of E. coli were compaired, it was 
observed that the lowest filament-inducing concentration of ceftazidime increased 
from 2 mg/L (SD 3.9) to 8 mg/L (SD 9.0) (not signifiant), and that the highest 
filament-inducing concentration increased from 8.3 (SD 6.1) to >50 mg/L (p 0.0001). 
Similarly, both values were also significantly higher for cefotaxime in ESBL-positive 
isolates (p 0.006 and 0.0001 at the lowest and highest concentrations, respectively). 
Comparison of antibiotics 
Ceftazidime induced the production of filaments in 30 isolates, compared with 26 
that were induced using cefotaxime (Table 1. and 2.). 
Overall, a trend towards larger filament-inducing dose ranges was shown with 
ceftazidime (mean 29.9 mg/L, SD 18.7) when compared with cefotaxime (mean 22.5 
mg/L, SD 18.9) (p 0.083). For E. coli, the filament-inducing dose range was signifi-
cantly wider following exposure to ceftazidime exposure (p 0.006). Overall, the MICs 
of ceftazidime and cefotaxime were significantly correlated (r 0.882, p <0.0001), 
even when highly cefotaxime-insusceptible isolates of Pseudomonas were included. 
The highest filament-inducing concentrations of ceftazidime and cefotaxime were 
significantly correlated (r 0.803, p 0.0001) when the data for all isolates are com-
bined. 
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Table 1. Concentration dependency of ceftazidime-induced filaments  
Concentration: 0 0.1 1 5 10 20 30 40 50 MIC  ratio 
Eco ATCC - + + + + + + +  0.125 80-320 
Eco 1 - + + ++      0.19 0.5-26 
Eco 2 -  + ++      0.19 0.5-26 
Eco 3 -    + +    0.38 26-53 
Eco 4 -  + +      0.19 5.3-26 
Eco 5 - ++ + +      0.094 1.1-53 
Kpn ATCC - + + + +     0.19 0.53-53 
Kpn 1 -   + +     0.125 40-80 
Kox 2 -   + + + +   1 5-30 
Kpn 3 -         0.032 - 
Kpn 4 -    +     0.25 40 
Kpn 5 -   + +     0.125 40-80 
Pae ATCC -  + + ++ ++ +   1 1-30 
Pae 1 -  ++ ++ ++ ++ + + + 0.5 2- >100 
Pae 2 -  + + + + ++ ++ + 32 0.03- >1.6 
Pae 3 -  + ++ ++ ++ ++ ++ ++ 1 1- >50 
Pae 4 -  + + ++ + + + + 0.5 2- >100 
Pae 5 -  + ++ ++ ++ ++ ++ ++ 1 1- >50 
Acb 1 -  + ++ ++ ++ ++ + + 1.5 0.7- >33 
Ac spp 2 -     + + ++ ++ 8 2.5- >6.3 
Acb 3 -   + + +    1.5 3.3- 13.3 
Acb 4 -  ++       1.5 <= 0.7 
Acb 5 -  ++ ++ ++ + + + + 3 0.3- 16.7 
            
Eco ESBL 1 -     + + + + 1.5 13.3-33.3 
Eco ESBL 2 -  + + + + + + + 3 0.33-16.6 
Eco ESBL 3 -         24 - 
Eco ESBL 4 -         16 - 
Eco ESBL 5 -  + + + + + ++ ++ 3 0.33-16.6 
Eco ESBL 6 -    ++ + + + + 8 1.25-6.25 
Eco ESBL 7 -         48 - 
Kpn ESBL 1 -         48 - 
Kpn ESBL 2 -         24 - 
Kpn ESBL 3 -   + + + + + + 4 1.25-12.5 
Kpn ESBL 4 -  + + + + + + + 2 0.5-25 
Kpn ESBL 5 -   + +     2 2.5-25 
Kpn ESBL 6 -   + + + +  + 0.19 0.53-53 
Kpn ESBL 7 -         >256 - 
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Table 2. Concentration dependency of cefotaxime-induced filaments  
Concentration:  0 0.1 1 5 10 20 30 40 50 MIC  ratio 
Eco ATCC - + +       0.064 1.6-15.6 
Eco 1 - ++ ++       0.125 0.8- 8 
Eco 2 - ++ +       0.064 1.6-15.6 
Eco 3 - + +       0.125 0.8- 8 
Eco 4 - + +       0.094 1.1-10.6 
Eco 5 - ++ ++ +      0.094 1.1-53 
Kpn ATCC - + + +      0.047 2-106 
Kpn 1 -  + + +     0.064 15.6-156 
Kox 2 -  + + + + + + + 0.38 2.6-132 
Kpn 3 -         0.016 - 
Kpn 4 - + +       0.064 1.6-15.6 
Kpn 5 - +        0.064 <=1.6 
Pae ATCC -   + + ++ +   24 0.2-1.25 
Pae 1 -   + + + +   8 0.6- 3.8 
Pae 2 -      + + + >32 0.9->1.6 
Pae 3 -   ++ ++ ++ ++ ++ ++ >32 0.2->1.6 
Pae 4 -   + ++ ++ + + + 8 0.6->6.3 
Pae 5 -   + ++ ++ ++ + + >32 0.2->1.6 
Acb 1 -   ++ ++ ++ ++ ++ ++ 8 0.6->6.3 
Ac spp 2 -   + ++ ++ ++ ++ ++ >32 0.2->1.6 
Acb 3 -   + ++ +    6 0.8- 3.3 
Acb 4 - + + ++ + + + + + 4 0.03->12.5 
Acb 5 -  + ++ ++ ++ ++ ++ ++ >32 0.03->1.6 
            
Eco ESBL 1 -    + + + +  0.75 13.3-53.3 
Eco ESBL 2 -         >32 - 
Eco ESBL 3 -         >32 - 
Eco ESBL 4 -         >32 - 
Eco ESBL 5 -         >32 - 
Eco ESBL 6 -      + + + 12 2.5-4.2 
Eco ESBL 7 -         >32 - 
Kpn ESBL 1 -         >32 - 
Kpn ESBL 2 -         >32 - 
Kpn ESBL 3 -         >32 - 
Kpn ESBL 4 -         >32 - 
Kpn ESBL 5 -     + +   0.64 31.3-46.9 
Kpn ESBL 6 -      + + + 6 5-8.3 
Kpn ESBL 7 -         >32 - 
 
Eco: Escherichia coli, Kpn: Klebsiella pneumoniae, Kox: Klebsiella oxytoca, Pae: Pseudomonas aeruginosa, 
Acb: Acinetobacter baumanii, Ac spp: Acinetobacter species, ESBL: extended spectrum ß-lactamase; ratio: 
minimum or maximum filament-inducing dose/MIC. 
+ short filaments (3-10 rods) 
++ long filaments (>10 rods) 
- or blank: absence of filaments (rods or debris) 
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Discussion 
The viable counts of E. coli were reduced following exposure to ceftazidime or 
cefotaxime, even at sub-MIC or MIC levels, compared with controls. At low concen-
trations, this may reflect filament formation rather than bacterial killing. This obser-
vation is explained by the fact that even large filaments count as 1 cfu.2,3,30-32 Most 
isolates produced large filaments (more than ten cell lengths) at a certain dose 
range, but only short filaments were encountered in Klebsiella spp., and some 
isolates did not produce filamentous forms at all. The absence of filament production 
by one of the K. pneumoniae isolates (Kpn 3) can be explained by the very low MICs 
of both antibiotics for this isolate, with filaments perhaps being formed at concentra-
tions <0.1 mg/L, which were not tested in the present study. In contrast, high MICs 
serve as an explanation for all other isolates that failed to produce filaments, as 
filament-inducing concentrations were correlated significantly with MICs. It was 
concluded that the relative degree of PBP-binding, which is reflected by the change 
in morphology, probably differs for each combination of antibiotic and bacterial 
family, genus or isolate.  
In support of this hypothesis, patterns among families, genera or isolates were 
recognisable. Within the Enterobacteriaceae, a pattern of short dose ranges for 
filament production at low ceftazidime and cefotaxime concentrations was observed, 
which was clearly related to the low MICs for these isolates. For Pseudomonas and 
Acinetobacter spp., filaments were induced by ß-lactams up to high concentrations. 
For most combinations, filament induction starts at subMIC or MIC levels, but may 
extend to concentrations far above the MIC. Only for Acinetobacter isolates was the 
highest filament-inducing concentration relatively low (14 x MIC). In ESBL- positive 
isolates, filament induction may still be present, but filament-inducing concentrations 
are shifted towards higher levels compared with those for non-ESBL producing 
isolates of the same genus. Ceftazidime induced filament production in more isolates 
than did cefotaxime, and particularly in some ESBL-positive isolates. Apparently, the 
ESBLs were more active against cefotaxime, which was reflected by the relatively 
higher MICs for these isolates. Some isolates, especially Pseudomonas and Acineto-
bacter spp. and ESBL-positive isolates, showed filament production at the highest 
antibiotic concentrations tested, which suggests the possibility of filament production 
at even higher antibiotic concentrations. 
The most important conclusion of this study is that extensive production of filaments 
may occur during exposure of relatively insusceptible microorganisms to clinically 
relevant concentrations of antibiotics. Such filament induction may cause exagger-
ated release of endotoxin, and should be regarded as a negative phenomenon. In 
order to prevent further augmentation of the already existing risks of antibiotic 
resistance, empirical antibiotic treatment in the early stages of serious infections 
should probably include relatively high concentrations or continuous dosing of 
antibiotics. 
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CHAPTER 6 
Pathophysiology of in-vitro induced 
filaments, spheroplasts and rod-shaped 
bacteria in neutropenic mice 
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Abstract 
This study compared in-vitro properties and in-vivo effects of Escherichia coli fila-
ments, spheroplasts and normal cells in a murine thigh infection model. E. coli was 
exposed to ceftazidime, meropenem, or saline to obtain filaments, spheroplasts or 
normal bacilli, which were then injected into neutropenic mice. After 24 h, morphol-
ogy, cfu, local and circulating endotoxin levels, cytokine levels and mortality were 
recorded, and correlations between bacterial and host parameters of infection were 
investigated. Filaments and spheroplasts contained more endotoxin/cfu than con-
trols. Histological studies showed that morphologically altered bacteria changed into 
rod-shaped cells in the absence of antibiotics. Bacterial spread to the liver was 
significantly higher in mice challenged with rod-shaped cells, compared with antibi-
otic-exposed bacteria (p 0.007). Muscle endotoxin levels correlated significantly with 
circulating interleukin(IL)-6 and tumour necrosis factor(TNF)-α and both pro-
inflammatory cytokines were correlated significantly (p 0.011). Despite a tendency 
toward higher local and systemic concentrations of endotoxin in the filament group, 
inflammatory responses and survival did not differ between groups. It was concluded 
that morphologically altered bacteria contain more endotoxin and can regain a rod 
shape after withdrawal of antibiotics, while non-antibiotic-exposed bacteria show 
greater spread to the liver. There was a clear intra-individual relationship between 
local endotoxin, systemic endotoxin, TNF-α and IL-6 production, but these parame-
ters did not differ among groups. 
Introduction 
Endotoxin, or lipopolysaccharide, released from the bacterial cell wall is the most 
important mediator in the pathogenesis of Gram-negative sepsis.1-10 Endotoxin 
release initiates a complex cascade involving production of endogenous mediators by 
the immune system of the host. The most important pro-inflammatory mediators are 
tumour necrosis factor (TNF)-α, interleukin(IL)-1, and IL-6.11 In low concentrations, 
these cytokines augment host defense.12-14 However, exaggerated release, which can 
be triggered by an overload of endotoxin, can cause pathofysiological effects result-
ing in shock and death.15-18 Shenep et al.19 demonstrated an exaggerated release of 
endotoxin after bacterial exposure to cell wall active antibiotics, but this response 
was absent when rapidly acting bactericidal agents were used. In addition, other 
investigators have shown variations in endotoxin-liberating capacity among different 
ß-lactam antibiotics.10,20,21 
Penicillin-binding proteins (PBPs) are enzymes anchored in the cytoplasmic mem-
branes of bacteria. PBPs, particulary PBP-1, PBP-2, and PBP-3, have significant 
biological functions, including determination of cell shape, phage resistance, induc-
tion of capsule synthesis, and regulation of autolysis.15,22-24 During exposure of 
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Gram-negative bacteria to low ceftazidime concentrations, PBP-3 inhibition occurs, 
leading to formation of bacterial filaments. It has been shown previously that bacte-
rial filaments are capable of releasing large amounts of endotoxin from their cell 
walls in-vitro.22 PBP-2 inhibition, which occurs during meropenem exposure, leads to 
formation of spheroplasts.25 
In contrast to filaments, spheroplasts contain lower endotoxin concentrations, 
comparable to those of rod-shaped cells.24,26 On the basis of these observations, it is 
possible that antibiotic-induced filament formation, in contrast to spheroplast forma-
tion, may have adverse clinical effects because of excessive endotoxin release. To 
test this hypothesis, the present study challenged neutropenic mice with filaments, 
spheroplasts or rod-shaped Escherichia coli cells in a murine thigh muscle model of 
infection.27-29 The in-vitro properties of the different inocula were studied with 
respect to morphology and the endotoxin content/cfu, local growth, local and sys-
temic endotoxin concentrations, morphology and systemic spread. Finally, the 
mortality rate and the plasma concentrations of the pro-inflammatory cytokines TNF-
α and IL-6 were determined, as parameters of both clinical effects and host de-
fence.11,14,17,30 
Materials and methods 
Mice 
Female outbred Swiss mice (aged 6-8 weeks, weight 20-30 g) were used for the 
experiments. Mice were bred by Harlan (Horst, The Netherlands) and arrived in the 
Central Animal Laboratory 2 weeks before the start of the experiments. Mice were 
held in a specific pathogen-free unit in filter-top cages with beds of sterilised saw-
dust. Food (Hope Farms, Woerden, The Netherlands) and acidified water were 
supplied at libitum. The temperature was kept at 20-24°C, with a relative humidity of 
50-60%, 15 air changes/h, and light and dark periods of 14 and 10 h, respectively. 
All experiments were approved by the Ethical Committee on Animal Experiments of 
the University Medical Centre Nijmegen, The Netherlands. 
Induction of neutropenia and anaesthesia 
On day -4, all mice received cyclophosphamide (Endoxan-ASTA; Dagra, Diemen, The 
Netherlands) 150 mg/kg subcutaneously to induce neutropenia. On day -1, a second 
dose of 100 mg/kg was given. Leucocyte counts and differentiation confirmed a 
neutropenia of < 0.1 x 106 leukocytes/L in each of the eight mice examined. During 
injections, the mice were anaesthetised with ether. 
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Microorganisms 
E. coli strain ATCC 25922 was used for all experiments. The MICs of ceftazidime and 
meropenem for this strain were 0.25 and 0.025 mg/L, respectively, as determined by 
Etest and broth microdilution methods.31,32 Bacteria were stored at -80°C and subcul-
tured on blood agar 2 days before the experiments. Subsequently, two colonies were 
inoculated into 10 mL of Mueller-Hinton broth and incubated overnight to obtain a 
culture containing c. 3 x 108 cfu/mL; this was diluted in triplicate with Mueller-Hinton 
broth in pyrogen-free glass test tubes to a concentration of 1 x 106 cfu/mL. After 
mixing, either ceftazidime, meropenem or saline was added (see below); this was 
followed by incubation for 4 h to induce filaments, spheroplasts or normal-shaped 
bacilli, respectively. Before injection, bacterial suspensions were mixed, diluted 1:10, 
washed twice and resuspended in saline at 37°C. 
Antibiotics 
Ceftazidime (Glaxo SmithKline, Zeist, The Netherlands), and meropenem (Astra-
Zeneca, Zoetermeer, The Netherlands)were used at concentrations of 0.125 and 
0.0125 mg/L, respectively (0.5 x MIC, for both drugs), to induce in-vitro morphologi-
cal changes with a minimum effect on bacterial growth. An aliquot (25 μL of either a 
ceftazidime 0.05 mg/mL solution or a meropenem 0.005 mg/mL solution was added 
to a test tube containing 10 mL of E. coli suspension. After discarding the same 
volume from the test solution, a ceftazidime concentration of 0.125 mg/L or a 
meropenem concentration of 0.0125 mg/mL was obtained. In a control tube 25 μL of 
the bacterial suspension was discarded and replaced with 25 μL of saline. 
Blood and tissue collection 
Blood specimens were collected from the retro-orbital plexus by eye extraction and 
were stored in sterile pyrogen-free Falcon tubes (Becton Dickinson, Franklin Lakes, 
NJ, USA). These tubes contained 10 μL of a 5000 U/mL pyrogen-free heparin solu-
tion (Leo Pharmaceutical Products, Weesp,The Netherlands). The tubes were placed 
immediately on ice and then centrifuged for 5 min to obtain plasma samples. Undi-
luted plasma was collected in Eppendorf tubes and frozen at -80°C until cytokine 
levels were determined. Plasma (0.5 mL) was aspirated in a sterile, pyrogen-free 
syringe (Monoject, Kendall, Ballymoney, Northern Ireland), diluted 1:10 in saline, and 
stored in pyrogen-free Falcon tubes at -80°C until limulus amoebocyte assays could 
be performed. Liver, spleen and thigh muscles were removed aseptically, immersed 
in saline, weighed, and then homogenised in a tissue grinder. Serial dilutions of 
homogenised tissues were plated on sheep blood agar. After overnight incubation at 
37°C, the number of cfu/g tissue was calculated. 
Endotoxin assay 
Endotoxin concentrations in plasma and muscle were determined by a chromogenic 
limulus amoebocyte assay (KabiVitrum, Amsterdam, The Netherlands), according to 
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the manufacturer’s instructions, at the Laboratory of Haematology, University Hospi-
tal Groningen, The Netherlands. 
TNF-α and IL-6 
Circulating TNF-α was detected by a radioimmunoassay developed and validated 
locally, and IL-6 concentrations were determined by ELISA (Biosource International, 
Camarillo, CA, USA). The detection limits of the two assays were 40 pg/mL and 30 
pg/mL, respectively. 
Effects of changes in morphology 
Changes in the length of filaments and the shape of spheroplasts during the in-vitro 
part of the study were determined following Gram’s stain. In-vivo morphology after 
24 h was assessed in haematoxylin-eosin-stained histological sections of muscle, liver 
and spleen, using light microscopy with magnifications of x 400 and x 1000. The 
effects of centrifugation, dilution, and the washing and mixing steps on morphology 
during the preparation of inocula were checked by examining Gram’s stains of cells 
at several time-points during the procedure. Bacterial counts, endotoxin content and 
the relationship between these parameters in inocula were also studied. In addition, 
initial test suspensions containing 105 and 106 cfu/inoculum of E. coli bacilli (eight 
mice for each inoculum size) and 10 4  and 105 cfu/inoculum of E. coli filaments (4 
mice for each inoculum size) were used to define the inoculum size requiredto obtain 
mice with severe sepsis and 100% survival after 24 h. The effectiveness of cyclo-
phosphamide for the induction of neutropenia was checked by measuring leucocyte 
counts and differentiation using light microscopy of blood smears from eight mice. 
Sepsis and mortality studies 
On each test day, 12 neutropenic mice were randomised between inoculation into 
the thigh muscle with 0.1 mL of filament solution, 0.1 mL of spheroplast solution, or 
0.1 mL of control solution. In each experiment, four mice per group were investi-
gated. The mice were kept in cages for 24 h following inoculation, and then anaes-
thetised with ether and killed. Immediately thereafter, blood was collected from the 
retro-orbital plexus for endotoxin and cytokine-assays. Liver, spleen and thigh 
muscles were removed surgically, homogenised and plated on agar to determine 
bacterial counts. Parts of the homogenates of thigh muscles were stored in pyrogen-
free tubes for endotoxin assays. The experiments were performed in duplicate on 
two separate days. 
In a separate experiment, mortality was investigated in 12 mice. Mice were random-
ised between inoculation with bacterial filaments, spheroplasts or rod-shaped cells in 
thigh muscles and then kept in cages and observed until death occurred. 
 64 
Statistical analysis 
Statistical analysis was performed using the SPSS v.10.0 package for Windows SPSS 
Inc., Chicago, IL, USA) and GraphPad Prism v.3.0 (GraphPad Software Inc., San 
Diego, CA, USA). Levene’s test for equality of variances was used to determine 
whether parameters were distributed normally. Differences in viable counts, survival, 
endotoxin concentrations and cytokine concentrations were analysed by multivariate 
analysis (ANOVA) for normally distributed parameters, followed, when appropriate, 
by post-hoc t-tests. Parameters without a normal distribution were analysed with the 
non-parametric Kruskal-Wallis test, followed by the Mann-Whitney test to investigate 
differences among groups. Correlations among parameters with a normal distribution 
were determined with the Pearson correlation test. For non-normally distributed 
parameters the non-parametric Spearman’s rank correlation test was applied. Statis-
tical tests were considered significant at p< 0.05. 
Results 
Comparison of filaments, spheroplasts and normal E. coli cells in-vitro. 
Incubation with ceftazidime resulted in the formation of filaments, whereas exposure 
to meropenem resulted in 100% formation of spheroplasts. Morphological studies 
demonstrated filaments with a length of four to eight cells after the centrifugation, 
dilution and mixing procedures. The morphology of the spheroplasts and controls did 
not change during these procedures. 
Table 1. summarises the viable counts, endotoxin concentrations and ratios of 
endotoxin/cfu for filaments, spheroplasts and controls, respectively. From these data, 
it was calculated that filaments and spherolasts From these data can be concluded 
that filaments and spheroplasts contain 13.49-fold and 5.36-fold, respectively, more 
endotoxin/cfu, than normal cells. Assuming that the characteristics of filaments are 
equivalent to those of rod-shaped cells, it was expected the amount of endotoxin/cfu 
(x 1000) would vary between 9.52 and 19.04 (4 x 2.38 and 8 x 2.38, respectively), 
taking into account that the length of one filament was the length of four to eight 
normal cells; however, the actual value was up to 3.4-fold higher than expected. 
 
 65 
 
Table 1. Cfu, endotoxin levels and the relationship between these two parameters for different cell-type 
inocula 
Morphology cfu/mL endotoxin 
(U/mL) 
Ratio endotoxin/cfu 
(U/cfu) x 1000 
 
Filaments 8.1 x 104 2600 32.10  
Spheroplasts 9.8 x 104 1250 12.76  
Controls 6.3 x 105 1500 2.38  
 
Survival studies 
When eight neutropenic mice were challenged intra-muscularly with 1x106 cfu of 
normal E. coli, only one mouse survived for 24 h (a survival of 12.5%). Challenge of 
eight mice with an inoculum of 105 of normal E. coli resulted in 100% survival after 
24 h. Similarly, challenge of four mice with either 104 or 105 cfu of E. coli filaments in 
100% survival after 24 h. On the basis of these findings, a maximum inoculum of 105 
cfu/mouse was chosen for controls in further experiments. 
In the main survival experiment, the survival times of infected mice were 42.25 (SD 
9.5, range 28-47 h), 41.25 h (SD 9.5, range 28-47 h) and 42.25 h (SD 11.5, range 
24-47 h) for filament-exposed, spheroplast-exposed and control mice, respectively, 
with 100% mortality after 47 h, irrespective of the group. Thus, at the time when 
measurements were performed in the sepsis studies, the mice were suffering from a 
severe sepsis, leading to death within 24 h from that time-point. 
Sepsis studies 
At 24 h after inoculation, bacteria were identified readily in the perivascular and 
perineural spaces in haematoxylin-eosin-stained thigh muscle sections. However, 
despite injection of filaments, only normal-shaped Gram-negative bacilli were ob-
served. No bacteria were identified in histological sections of liver and spleen using 
lightmicroscopy, despite bacterial counts of 104-106 cfu/g of tissue, perhaps because 
of the architecture of these tissues. 
Fig 1. shows the bacterial counts in muscle, liver and spleen at 24 h after inoculation 
with normal bacilli, filaments or spheroplasts. Cfu in liver tissue showed significant 
differences between groups (p 0.025), with the highest amount of cfu in liver ho-
mogenates from controls. There were also significant differences between sphero-
plasts and controls (p 0.015), between filaments and controls (p 0.027), and be-
tween all antibiotic-exposed bacteria and controls (p 0.007). Although the same 
trend of lower cfu counts was seen in spleen tissue infected with spheroplasts, the 
bacterial counts did not differ significantly among groups, (p 0.1644). Similarly, no 
significant differences in viable counts were observed after 24 h in thigh muscles. Cfu 
in muscle, liver and spleen did not show significant correlations with local or systemic 
levels of endotoxin, TNF-α or IL-6. 
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Figure 1. Mean (SD) bacterial counts (cfu/g) and in murine thigh muscle, liver and spleen 
at 24 h after inoculation with different bacterial cell types 
 
 
Plasma and muscle endotoxin concentrations are shown in Table 2. Allthough mean 
values suggest higher endotoxin concentrations in the plasma and muscle of mice 
injected with filaments, the differences among groups did not reach significance (p 
0.063 for filaments vs. spheroplasts). However, there was considerable variation in 
the local endotoxin levels, reflected in large standard deviations. Nevertheless, 
significant correlations could be shown between plasma and muscle endotoxin levels 
(p 0.014). 
Also shown in Table 2. are the mean levels of plasma TNF-α and IL-6. Although 
these parameters did not differ among groups, there was a significant correlation 
between muscle endotoxin and plasma IL-6 levels (p 0.025) and between muscle 
endotoxin and TNF-α levels (p 0.03). There was no significant correlation between 
plasma endotoxin and IL-6 or TNF-α levels (p 0.074 and 0.09, respectively). There 
was a significant correlation between plasma TNF-α and IL-6 levels (p 0.011). 
 
 
Table 2. Mean muscle endotoxin, plasma endotoxin, tumour necrosis factor(TNF)-α and interleukin(IL)-6 
levels at 24 h after inoculation of neutropenic mice with different bacterial cell types 
Cell type 
(number of mice) 
Muscle LPS 
(U/mL) Mean (SD) 
Plasma LPS 
(U/mL) Mean (SD) 
plasmaTNF-α 
(pg/mL) Mean (SD) 
plasma IL-6  
(pg/mL) Mean (SD) 
Filaments (N=8) 262 363 (141592) 91 (32) 288 (477) 18 229 (15 163) 
Spheroplasts (N=8) 139 670 (109900) 31 (25) 268 (506) 29 229 (32 378) 
Controls (N=8) 253 213 (179257) 66 (62) 120 (124) 37 183 (31 991) 
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Discussion 
The in-vitro part of this study demonstrated a higher endotoxin content/cfu in 
antibiotic-exposed bacteria than in controls. In contrast to previous findings,24,26 this 
study also demonstrated higher endotoxin contents in spheroplasts. This could be 
caused by the induction of spheroplasts with meropenem, which binds to PBP-2 and 
PBP-3. In previous studies,24 imipenem, which binds to PBP-1 and PBP-2 was used to 
induce spheroplasts. Thus, it is possible that the toxic properties of spheroplasts may 
differ according to the inducing antibiotic and its affinity for specific PBPs. 
The study also revealed that the higher endotoxin content of filaments could not be 
explained simply by normal bacterial growth without septation. It is not clear 
whether a higher density of endotoxin molecules in the cell wal, a larger cell surface 
or a change in the endotoxin molecule itself, contributed to these higher than ex-
pected endotoxin levels. However, the findings correlate with those of Jackson and 
Kropp33 for Pseudomonas isolates exposed to sub-MIC concentrations of ceftazidime. 
The present model showed that filaments were able to regain normal shapes after 
withdrawal of antibiotics. However, there was a difference in the dissemination 
pattern of bacteria during the first 24 h of sepsis, though local bacterial counts in 
thighs were equal after 24 h. Dissemination of bacteria to the liver occurred signifi-
cantly more efficiently in the group infected with rod-shaped cells, compared with 
the groups infected with antibiotic-exposed bacteria. Differences in the systemic 
spread of morphologically altered microorganisms may be explained by differences in 
size or changes in the vitality of bacteria, causing inhibition of migration of the larger 
forms. Chen et al.34 have described altered motility of Burkholderia pseudomallei 
following exposure to filament-inducing antibiotics. A second explanation could 
involve a greater vulnerability of morphologically altered bacteria to host defence 
mechanisms, e.g., differences in serum bactericidal effect. The fact that no signifi-
cant difference in spread to spleen tissue was detected might be explained by the 
overwhelming numbers of cfu in spleen tissue masking more subtle differences. 
Antibiotic-induced morphological changes, and changes in dissemination of E. coli, 
did not affect parameters of severity of infection and survival, perhaps because the 
bacteria were able to septate again after withdrawal of the antibiotics, and thus 
regained the morphological characteristics, and probably the pathogenicity, of 
controls. Furthermore, the numbers of cfu in thighs were the same in all groups after 
24 h. Alternatively, the infection may be so severe that a reltively low endotoxin 
content associated with the natural forms of E. coli may already have a maximum 
effect. In all groups, the animals developed a severe infection within the first 24 h, 
leading to death within 48 h of the start of the experiment. The relative resistance of 
mice to endotoxin could also be an explanation; thus, the amounts of endotoxin 
associated with the various morphological forms might not have contributed to 
death. Finally, it is also possible that endotoxin is retained in the membranes of 
filaments, i.e., locally at the site of infection, for a longer period of time, thus expos-
ing the host to toxic molecules to a lesser extent. 
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The study showed a clear relationship between muscle and plasma endotoxin con-
centrations, and between local endotoxin concentrations and circulating levels of IL-6 
and TNF-α. Although local and circulating endotoxin levels were related significantly, 
the correlation between plasma endotoxin levels and both cytokines did not reach 
significance. However, multiple plasma factors, e.g., protein binding, might influence 
the concentration and clearance of circulating lipopolysaccharide. The relationship 
between endotoxin en cytokines has beenn investigated in other models and in 
human studies.17,35-40 It will be interesting to focus further studies with the model on 
the inflammatory responses that occur during the first hours after inoculation, and on 
the host reactions to milder infections, in order to investigate more subtle differ-
ences. Another valuable use of the model might involve a situation in which the 
presence of antibiotics is maintained for longer, in order to keep the bacteria in their 
altered shapes. 
In conclusion, the in-vitro part of this study confirmed the finding that filaments 
contain more endotoxin in their cell wall than do controls.41 However, in contrast 
with earlier findings, spheroplasts also contained more endotoxin compared with 
normal bacilli. Local endotoxin, plasma endotoxin and pro-inflammatory cytokine 
levels showed a clear correlation in the present model, and endotoxin levels in 
muscle showed a significant correlation with plasma endotoxin levels. From the 
present study of overwhelming and rapidly fatal septicaemia, it is clear that filaments 
and spheroplasts are potentially more virulent and pathogenic than rod-shaped cells, 
and that they are able to regain normal shapes after withdrawal of antibiotic treat-
ment. Bacteria that have been in an altered morphological shape show different 
dissemination characteristics. 
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CHAPTER 7 
Bacterial morphology and cytokine 
induction by four ß-lactam-antibiotics in 
infected neutropenic mice 
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Abstract 
Objectives: ß-lactam antibiotics induce morphological changes in Gram-negative 
bacteria by inhibiting Penicillin Binding Proteins (PBPs). Aztreonam and ceftazidime 
induce formation of filaments (unseptated strands) by inhibition of PBP-3. Moreover, 
the PBP-affinity of ceftazidime is concentration dependent, causing bacterial filament 
formation at low concentrations and immediate bacteriolysis at high concentrations. 
Filaments contain high amounts of endotoxin.  
Imipenem and meropenem inhibit PBP-2, which leads to induction of spheroplasts 
(large rounded bacteria). Spheroplasts contain low amounts of endotoxin. Host 
exposure to endotoxin induces production of pro-inflammatory cytokines, which are 
associated with shock and death when they are present at high concentrations.  
Methods: The effects of four ß-lactam antibiotics on bacterial growth, morphology 
and systemic spread, as well as on endotoxin and cytokine responses in neutropenic 
mice with intramuscular Escherichia coli infections were studied. Local bacterial 
growth, morphology and systemic spread were also studied in intraperitoneal Es-
cherichia coli infections.  
Results: Intraperitoneal infections ran a more fulminant course than intramuscular 
infections, with more systemic spread of bacteria. Filaments were shown in both 
models after treatment with aztreonam or ceftazidime, despite of the theory that 
high ceftazidime-concentrations should lead to immediate bacterial lysis, without 
preceding morphological changes of bacteria. Spheroplasts were encountered in 
meropenem or imipenem treated mice. Generally, all antibiotic treated mice showed 
higher TNF-α levels; concentrations were highest in mice with filaments (TNF-α= 758 
pg/mL versus 283 pg/mL, p 0.046 for filament-inducing agents compared with 
controls), which was in line with our hypothesis.  
Conclusion: We conclude that PBP-affinity of ß-lactam antibiotics may have conse-
quences for cytokine responses, which may be associated with altered bacterial 
toxicity. 
Introduction 
ß-lactam-antibiotics covalently bind to and subsequently inhibit Penicillin Binding 
Proteins (PBP), located in the cytoplasmic membrane of bacteria.1 Older ß-lactams, 
like benzyl-penicillin, bind to all PBPs, leading to lysis of bacteria without preceding 
morphological changes. Meropenem or imipenem inhibit PBP-2, causing formation of 
morphologically altered bacteria, called spheroplasts. Spheroplasts are viable, and 
have capacity to regain a normal shape once antibiotics are withdrawn.2 They con-
tain similar or slightly higher amounts of LPS (lipopolysaccharide, endotoxin) in their 
cell wall than untreated bacilli.2,3 Aztreonam and ceftazidime bind to PBP-3. Inhibition 
of PBP-3 leads to formation of filament-shaped bacteria. In-vitro studies showed that 
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these long strands of bacterial material are not only viable, but also capable of 
liberating large amounts of endotoxin during additional exposure to antibiotics.3-5 
The capacity of morphologically changed bacteria to spread to other organs is also 
altered.2,6 Endotoxin molecules, liberated from Gram-negative bacteria during antibi-
otic treatment,7-11 are capable of inducing the release of pro-inflammatory mediators 
by monocytes, such as Tumour Necrosis Factor-α (TNF-α) and interleukin-6 (IL-
6).12,13 In murine and human infections, local or systemic endotoxin concentrations 
and circulating cytokines are strongly correlated and may serve as a marker of sepsis 
severity.2,14,15 Cytokines augment host defense, but at high concentrations, as may 
be induced by an overload of endotoxin, cause clinical deterioration or even mortal-
ity.16-18 Shortly after the introduction of antibiotics, cases of severe clinical deteriora-
tion after the first dose of antibiotics were described, which were attributed to a 
sudden bacterial lysis with concomitant high endotoxin releases and cytokine re-
sponses.19-21 We hypothesize that antibiotic-induced alterations of bacterial morphol-
ogy contribute to this observation. Neutropenia is associated with marked increases 
of plasma TNF-α concentration after LPS injection and enhancement of LPS-induced 
mortality.22-24 
Despite of several in-vitro studies showing enhanced endotoxin contents of filaments 
compared with spheroplasts and rods, in-vivo studies on this subject, especially in 
severe sepsis in immunocompromised hosts, are scarce. 
 
The studies described in this paper aim at evaluating the effects of four ß-lactam 
antibiotics with gradually varying PBP-affinities on bacterial morphology, spread, 
endotoxin- and pro-inflammatory cytokine-production in severe Gram-negative 
infections in the neutropenic host. Both neutropenic intramuscular as neutropenic 
intraperitoneal infection models were applied and compared. 2,25,26 
Materials and methods 
Outline of the studies 
Comparison of intraperitoneal and intramuscular models, time course of 
morphological changes. 
Twelve mice received an intraperitoneal (ip) or intramuscular (im) inoculum of E. coli. 
Two h later (t = 0), 20 mg/kg ceftazidime was administered in the tail vein. In each 
group 3 mice were sacrificed 2 and 4 h later, to judge the time course of changes of 
bacterial morphology, growth and spread. 
 74 
Controlled study of 4 ß-lactam antibiotics in both models 
In two additional experiments, 31 neutropenic mice were used. At t = -2 h, an 
inoculum was given ip (N=15) or im (N=15). A negative control mouse received 
saline im. Two h after inoculation (t = 0 h), intravenous bolus injections of cef-
tazidime, aztreonam, meropenem, imipenem or saline were administered. Mice were 
sacrificed for tissue and plasma collection 4 h after start of antibiotic treatment (t = 4 
h). In previous studies, comparing various dosing regimens of ß-lactam antibiotics, 
both plasma TNF-α as plasma IL-6-concentrations showed significant differences 
between groups at this time point.27 Murine neutropenic models were used because 
severe sepsis, with concomitant high cytokine responses, can easily be induced in a 
reproducible manner.27 Moreover, neutropenic mice are more susceptible to the toxic 
or even lethal effects of endotoxin.22-24 
Mice 
Female Swiss mice, aged 6 to 8 weeks, weight 20-30 g, were used. Mice were bred 
by Harlan (Horst, The Netherlands) and were held at the SPF-unit (Specific Pathogen 
Free) in filter-top cages embedded with sawdust. Food (Hope Farms, Woerden, The 
Netherlands) and acidified water were supplied at libitum. Temperature was kept 
between 20 to 24°C, relative humidity to 50 to 60%, airchanges to 15 times/h, and 
duration of light and darkness to 14 and 10 h, respectively. 
Induction of neutropenia and anaesthesia 
On day -4, mice received cyclofosfamide (Dagra, Diemen, The Netherlands) 150 
mg/kg subcutaneously. A second dose of 100 mg/kg was administered on day -1. 
Leukocyte counts and differentiation confirmed a neutropenia of <0.1 x 106 leuko-
cytes/L in each of 8 mice tested. During injections, inhalation anaesthesia was given 
with isoflurane. 
Micro-organisms 
E. coli strain ATCC 25922 was used in all experiments. MICs for ceftazidime, aztreo-
nam, meropenem and imipenem were 0.25 mg/L, 0.125 mg/L, 0.023 mg/L, 0.125 
mg/L, respectively, as determined by Etest and broth microdilution methods. Bacteria 
were stored at -80°C and subcultured on blood agar two days before the experiment. 
Subsequently, an overnight culture was prepared by inoculation of two colonies in 10 
mL Mueller-Hinton broth and incubation at 37°C. Two h before start of the experi-
ment, 1 mL was diluted and resuspended in fresh MH-broth to obtain a standardised 
solution of bacteria in the log-phase. 0.1 mL of this solution was administered as an 
intraperitoneal (ip) or intramuscular (im) injection. Three tenfold dilutions of the 
inoculum were plated on sheep blood agar and incubated overnight at 37°C in 
triplicate. On the next day bacterial counts were performed manually. 
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Antibiotics and pharmacokinetic parameters 
For the model-comparing studies, ceftazidime (Glaxo SmithKline B.V., Zeist, The 
Netherlands) was used. In two subsequent studies, treatments with ceftazidime, 
aztreonam (Bristol-Myers Squibb, Woerden, The Netherlands), meropenem (Astra-
Zeneca, Zoetermeer, The Netherlands) and imipenem/cilastatin (Merck, Sharp and 
Dome, Haarlem, The Netherlands) were applied in both models. To rule out effects 
of differences in bacterial growth inhibition, doses were adjusted to MICs. Dosages 
were: 2 mg/kg (0.05 mg/mouse), 2 mg/kg (0.05 mg/mouse), 0.2 mg/kg (0.005 
mg/mouse) and 2 mg/kg (0.05 mg/mouse) iv for ceftazidime, aztreonam, mero-
penem and imipenem/cilastatin, respectively. Control mice, including a negative 
control, received 0.1 mL saline iv. 
In Swiss mice, plasma half-life and volume of distribution of ceftazidime were 10.8 
min and 4.1 mL respectively, as determined in previous studies by High Pressure 
Liquid Chromatography (HPLC) of plasma samples.27 According to these pharmacoki-
netic parameters, predicted plasma peak levels after 2 mg/kg ceftazidime iv are 12 
mg/L (49 x MIC). Time above MIC is predicted to be 6 x T½ = 64.8 minutes (27% of 
the study period). 
Blood and tissue collection 
To obtain plasma samples, blood was collected from the retro-orbital plexus in sterile 
pyrogen-free Falcon-tubes (Becton Dickinson, Franklin Lakes, NJ, USA), containing 
10 μl of pyrogen-free heparin (5000 U/mL) (Leo Pharmaceutical Products, Weesp, 
The Netherlands), immediately stored on ice, centrifugated at 500 x g during 5 
minutes and stored at -80°C until assays were performed. Organs and tissues were 
removed aseptically, weighed and homogenised in a sterilised tissue grinder. In the 
peritonitis model, a standardised piece of 1 x 1 cm of peritoneum was obtained with 
sterile scissors, weighed, diluted in saline, and homogenised. Serial dilutions of tissue 
homogenates were plated on sheep blood agar. After overnight incubation at 37°C 
bacterial counts were performed manually. Bacterial counts were expressed as 
cfu/organ, with the exception of peritoneal cfu, which were expressed as cfu/g, in 
order to correct for variations in sample size. 
 
Endotoxin and cytokine assays 
Endotoxin concentrations in plasma were measured with a chromogenic limulus 
amoebocyte (LAL) assay (Associates of Cape Cod Inc., Falmouth, MA, USA) accord-
ing to the prescriptions of the manufacturer. Plasma TNF-α and IL-6 were deter-
mined with radioimmunoassay (RIA)28 and ELISA (Biosource International, Camarillo, 
CA, USA), respectively. Detection limits of the assays were 40 and 150 pg/mL, 
respectively. 
 
Morphological studies 
Bacterial morphology was studied in sections of peritoneum, muscle, liver and spleen 
after Gram’s, haematoxylin-eosin (HE)- or fluorescent acridine orange (AO)- staining 
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techniques.29 Morphology was judged by a pathologist and one of the investigators 
using light and fluorescence microscopy at magnifications of 400 x and 1000 x. 
Bacteria were defined as filaments when a length of 3 or more rods was shown. 
Statistics 
Statistical analysis was performed using the SPSS package for Windows (SPSS 10.0, 
Chicago, IL, USA) and GraphPad Prism 3.0 (GraphPad software Inc., San Diego, CA 
USA). To judge whether parameters were normally distributed, Levene’s test for 
equality of variances was applied. Differences in viable counts, endotoxin- and 
cytokine-concentrations were analysed by multivariate analysis (ANOVA) for normally 
distributed parameters, followed when appropriate, by post-hoc t-tests. Parameters 
without a normal distribution were analysed with the non-parametric Kruskal-Wallis 
test, followed by the Mann-Whitney test to investigate differences among groups. 
Correlations among parameters with a normal distribution were determined with the 
Pearson correlation test. For non-normally distributed parameters Spearman’s rank 
correlation test was applied. Statistical tests were considered significant at p<0.05. 
Results 
Comparison of intraperitoneal and intramuscular models  
In this study the inoculum contained 1.8 x 108 cfu/mouse. Cfu in liver and spleen in 
intraperitoneally infected mice were significantly higher compared with intramuscu-
larly infected mice (2.8 x 107 cfu/liver (SD 4.0 x 105) versus 1.5 x 105 cfu/liver (SD 
2.9 x 104), p 0.0001 and 2.6 x 106 cfu/spleen (SD 2.2 x 106) versus 1.3 x 104 
cfu/spleen (SD 2.0 x 104), respectively, p 0.021, Fig 1.). Cfu in muscle, liver and 
spleen were moderately positively correlated.  
Within 2 h after administration of ceftazidime, filaments of a length of >10 rods were 
observed in the intramuscular model. Two h later, intramuscular filaments were 
longer than 15 rods. In the intraperitoneal model, filaments had a maximum length 
of 4 rods after 2 h and 7-8 rods after 4 h of treatment. In untreated mice, thigh 
muscles contained rod-shaped E. coli. 
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Fig. 1: Cfu of E. coli in peritoneal cavity, muscle, liver and spleen, 2 and 4 h after ceftazidime 20 mg/kg iv in
the intraperitoneal (left) and intramuscular (right) infection model 
 
Controlled study of ß-lactams in intraperitoneal infections 
Because the inocula applied in the first studies led to serious clinical deterioration of 
mice, a 1000-fold lower inoculum size (1.3 x 105 cfu/mouse) was chosen for induc-
tion of peritonitis in further experiments. In ceftazidime- or aztreonam-treated mice, 
filaments were shown intraperitoneally. Meropenem or imipenem treatment induced 
intraperitoneal spheroplasts. In liver and spleen bacteria could not be visualised by 
light or fluorescence microscopy, despite of high concentrations of bacteria in these 
organs. 
Cfu varied between 1.7 x 103 and 7.2 x 105 per piece of peritoneum and were highly 
variable, as shown by the standard deviations. Probably a variation of sample size 
plays a role (mean weight 0.0869 g, SD 0.01882, range 0.06-0.12). Intraperitoneal 
cfu were lower for aztreonam compared with imipenem treated mice: 2.7 x 104 cfu/g 
versus 2.2 x 105 cfu/g (p 0.05). Cfu in liver and spleen did not differ between groups. 
Clinical deterioration of mice severely hampered blood sampling, so endotoxin and 
cytokine studies could not be performed in this experiment. 
Controlled study of ß-lactams in intramuscular infections 
In thigh muscles of aztreonam- or ceftazidime-treated mice, large filaments were 
shown located in the perivascular space between the muscle cells (Fig 2.). After 
treatment with meropenem or imipenem, spheroplasts were encountered in the 
same areas. 
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Figure 2. Intramuscular E. coli filaments, acridine orange (1000 x) after ceftazidime iv 
Full colour illustration on page 132 
 
 
In the im experiment the inoculum size was 0.94 x 107 cfu/mouse. Mean cfu counts 
at t = 4 h are shown in Table 1. The lowest counts were found in the aztreonam 
group, in which filaments were extensively present. The difference of cfu between 
aztreonam- or imipenem-treated mice was significant (p 0.043). This finding is in 
concordance with the results of the peritonitis study described above. Systemic 
spread of bacteria did not differ between groups. 
 
 
Table 1. Local cfu, plasma endotoxin and cytokines in thigh infections 
Antibiotic (n) mean cfu muscle (SD) mean plasma  
endotoxin (SD) 
(U/mL) 
mean plasma 
TNF-α (SD) 
(pg/mL) 
mean plasma 
IL-6 (SD) 
(pg/mL) 
Ceftazidime (3) 1.1 x108  (1.2 x108) 1885 (674) 883 (605) 3590 (1301) 
Aztreonam (3) 6.8 x107  (2.6 x107) 1380 (105) 633 (991) 2743 (361) 
Meropenem (3) 1.9 x108  (1.4 x108) 2085 (939) 590 (191) 3047 (780) 
Imipenem (3) 2.0 x108  (3.0 x107) 2014 (861) 240 (99) 2603 (1166) 
Saline (3) 2.6 x108  (1.4 x108) 1459 (61) 283 (176) 2357 (1391) 
 
 
Mean endotoxin concentrations did not differ between groups (Table 1.). In Table 1. 
and Fig 3., mean values of plasma TNF-α and IL-6 concentrations are shown. Com-
pared with saline controls, all mice treated with antibiotics showed two to three-fold 
higher plasma concentrations of TNF-α (p 0.007), with the exception of imipenem-
treated mice. The difference between filament-inducing treatments and controls was 
significant (meanTNF-α= 758 pg/mL (SD 410) versus 283 pg/mL (SD 176) p 0.046 (p 
0.035 for aztreonam, p=0.083 for ceftazidime). For spheroplast-inducing agents 
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versus controls the difference was not significant (p 0.226). Though TNF-α values 
were higher in the filament groups than in the spheroplasts groups, differences were 
not significant (p 0.292). Remarkably, in the spheroplast groups, a trend of higher 
TNF-α and IL-6 values was shown in the meropenem group compared with the 
imipenem group. Mean IL-6 concentrations did not differ between groups. The 
correlation between muscle cfu and circulating endotoxin nearly reached significance 
(r = 0.612, p 0.06). Remarkably, muscle Cfus negatively correlated with TNF-α (r =-
0.65, p 0.042 and IL-6 (r = -0.476, p 0.164), while liver cfu were positively corre-
lated with TNF-α (r = 0.825, p 0.006) and IL-6 (r = 0.947, p 0.0001). Plasma TNF-α-
concentrations strongly correlated with plasma IL-6 (r =0.816, p 0.0001). Correla-
tions between plasma endotoxin and both cytokines were not significant. 
 
 
 
Figure 3. TNF-α and IL-6 at t = 4 h after ceftazidime, aztreonam, meropenem, imipenem or saline in the im-
model 
 
 
Discussion 
Our studies show that morphological changes of bacteria can be readily induced both 
in intraperitoneal and intramuscular murine infection by administration of ß-lactam 
antibiotics with specific PBP-binding properties. These morphological changes can 
also be clearly related to subsequent alterations of cytokine responses in the host. 
This may be harmfull, as several studies showed that the initial inflammatory re-
sponse directly correlates to early sepsis mortality in murine peritonitis.30,31 
Intraperitoneal infections ran a more fulminant course than intramuscular infections, 
with significant greater dissemination of microorganisms to liver and spleen, leading 
to severe clinical deterioriation, even with low inoculum sizes. In both models, local 
numbers of cfu at the site of infection were lower in aztreonam- compared with 
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imipenem-treated mice. Besides bacteriolysis, this decline can be explained by 
aztreonam-induced filament formation, since filament formation causes a decrease in 
numbers of cfu (one filament consists of many interconnected bacteria, but repre-
sents only one cfu). 
Plasma cytokines were highest during filament inducing treatments and lowest in 
imipenem-treated mice (Fig 3.). This finding is consistent with the previous findings 
of Prins et al.,32 who showed high endotoxin and cytokine responses in whole blood 
ex-vivo after exposure of E. coli to ceftazidime, compared with imipenem. Our 
findings are also in line with the studies of Yokochi et al. in non-neutropenic mice 
with intraperitoneal P. aeruginosa infections, who showed low systemic endotoxin 
and TNF-α concentrations during imipenem treatment, compared with meropenem33 
and ceftazidime-treatment.34 
In peritoneal infections we showed relatively short filaments (4-8 rods), compared 
with long filaments (>15 rods) in intramuscular infections, possibly because of 
differences in local ceftazidime-concentrations.35,36 Given the dose and peak level, it 
is remarkable that even in studies with 20 mg/kg ceftazidime, filaments are still 
formed. The short plasma half-life of ceftazidime in mice, which leads to a short 
exposure time of bacteria, may explain this observation. 
In contrast to high endotoxin concentrations of filament suspensions in-vitro,3,9 we 
were unable to demonstrate a relation between circulating endotoxin levels and 
bacterial morphology or treatment regimen. Clearance from the circulation, adher-
ence of endotoxin molecules to tissue and plasma components, as well as retainment 
in bacteria at the infection site may all explain this finding.37 Despite of the absence 
of differences between plasma endotoxin concentrations, plasma cytokines were 
higher in mice with filaments and in mice with more extensive systemic spread of the 
infection. Apparently, both factors contribute to a severe course of the infection. 
Similarly, in previous studies in rat peritonitis no differences in circulating endotoxin 
were shown between controls and antibiotic-treated mice, whereas all treatments led 
to significant higher circulating TNF-α-concentrations, especially in mice with fila-
ments.12 In the present study, a trend of higher concentrations of both cytokines was 
shown for meropenem compared with imipenem, although both antibiotics induced 
spheroplasts. This observation may be explained by differences of PBP-inhibiting 
properties of meropenem (PBP-2 and -3)38 and imipenem (PBP-1a, -1b and -2).39 
Similarly, in non-neutropenic mice with Pseudomonas aeruginosa -peritonitis, mero-
penem treatment also led to higher pro-inflammatory cytokine responses, compared 
with imipenem treatment.33 Vianna et al. also measured low TNF-α-concentrations 
after imipenem treatment in mice in a peritonitis model with cecal ligation and 
puncture, compared with mice treated with saline.11 In human in-vivo studies, 
measurements of plasma endotoxin during different treatment regimens often show 
inconclusive results,40,41 despite of clear differences between pro-inflammatory 
cytokine responses, especially when ceftazidime and imipenem-treatments are 
compared.40 
 81 
A limitation of our study was the fact that we have not been able to check the 
degree of cytokinemia in intraperitoneally infected mice, as the poor condition 
severely hampered plasma sampling. 
We conclude that the choice of antibiotics in sepsis therapy has important conse-
quences for cytokine responses, particularly during initial therapy. These responses 
may lead to severe toxic effects, especially in neutropenic hosts.22-24 Future studies 
should explore, whether alterations in bacterial morphology and subsequent en-
hancement of initial endotoxin-induced cytokine releases are related to clinical 
deterioration, and whether choices of antibiotics, combinations or dosing schedules 
can alter the clinical course of sepsis. 
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CHAPTER 8 
Continuous administration of PBP-2 and 
PBP-3 specific ß-lactams causes higher 
cytokine responses in murine 
Pseudomonas aeruginosa and Escherichia 
coli sepsis 
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Abstract 
Objectives: Initial antibiotic treatment of severe infections can lead to clinical deterio-
ration due to sudden endotoxin release and concomitant exaggerated inflammatory 
response. Antibiotic-induced morphological changes may contribute to this phe-
nomenon. High-dose ceftazidime, which inhibits penicillin-binding protein (PBP)-1 in 
Gram-negative bacteria, causes quick bacteriolysis and low endotoxin release. Low-
dose ceftazidime leads to PBP-3 inhibition, which causes bacterial filament formation, 
associated with high endotoxin releases. PBP-2-specific antibiotics induce sphero-
plasts, again associated with low endotoxin release. We hypothesized that antibiotic 
type, concentration and regimen influence bacterial morphology, endotoxin levels 
and inflammatory response.  
Methods: Neutropenic mice with Escherichia coli or Pseudomonas aeruginosa sepsis 
were treated with ceftazidime or meropenem 10-320 mg/kg as an intravenous bolus 
or as continuous tail vein infusions of 0.1 mL/h. Four h later, bacterial counts, mor-
phology, plasma endotoxin, pro-inflammatory cytokines (tumour necrosis factor-α 
(TNF-α) and interleukin-6 (IL-6)) and antibiotic concentrations were measured. 
Results: Continuous infusion of 80 mg/kg ceftazidime was the lowest dose preventing 
filaments in E. coli infections. Bolus treatment resulted in filament formation, irre-
spective of the dose. During continuous treatment, IL-6 and TNF-α-concentrations 
were higher compared with bolus treatment and controls for both antibiotics and 
both strains. A clear relationship between cfu counts in muscle and circulating IL-6 
was shown (r = -0.579, p 0.007), suggesting that plasma IL-6 is a valuable indicator 
of bacterial killing at the infection site.  
Conclusions: Our findings show that not PBP-affinity but the method of antibiotic 
administration is crucial during initial treatment of severe infections. 
Introduction 
Sepsis is a serious life-threatening condition needing prompt antibiotic treatment. 
Overall sepsis mortality is high (18% to 56%),1,2 with Gram-negative bacteria being 
causative in 20% of cases.3 Early and effective treatment, preventing severe inflam-
mation and concomitant organ dysfunction, is essential. However, early antibiotic 
treatment may sometimes induce unexpected clinical deterioration, possibly because 
of an exaggerated inflammatory response.4-7 
Endotoxin or lipopolysaccharide (LPS) is the central mediator in the pathogenesis of 
sepsis and its inflammatory response.8,9 There are strong relationships between 
endotoxin exposure and sepsis symptoms,10-12 as well as between bacterial endotoxin 
concentrations and production of pro-inflammatory cytokines, such as tumour necro-
sis factor-α (TNF-α) or interleukin-6 (IL-6).13-16 Bacterial endotoxin release after 
exposure to antibiotics depends on penicillin-binding protein (PBP)-binding character-
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istics of the antibiotic.17-19 PBPs are anchored in the bacterial cytoplasmic membrane. 
They determine cell shape, phage resistance, induction of capsule synthesis and 
regulation of autolysis.20 The ß-lactam antibiotic ceftazidime has a varying dose-
dependent binding affinity for different PBPs. High ceftazidime concentrations cause 
PBP-1 inhibition, quick bacterial lysis without morphological changes and low en-
dotoxin release. Low concentrations of ceftazidime cause PBP-3 binding, disabling 
bacterial septation capacity, leading to growth in filamentous forms (Fig 1.).21,22 
These filaments are associated with a high endotoxin release23,24 and high TNF-α and 
IL-6 production by exposed monocytes.25 In contrast, meropenem, which binds PBP-
2, causes formation of large rounded cells, called spheroplasts.26 In contrast to 
filaments, spheroplasts are not associated with higher endotoxin releases.16,23 
In this study, we speculated that antibiotic type, initial dosing regimen and concen-
tration levels may shift PBP-affinities, aler bacterial morphological responses and 
thereby influence endotoxin release and clinical effect. We compared the effects of 
two different ß-lactam antibiotics (ceftazidime and meropenem) in two dosing 
schedules (continuous and intermittent) in sepsis induced by two strains of bacteria, 
using a murine model that has been previously shown to provide the most uniform 
sepsis response patterns.16  
Materials and methods 
Mice 
Female outbred Swiss mice (aged 6-8 weeks, weight 20-30 g) were used in all 
studies. Mice were bred by Harlan (Horst, The Netherlands) and arrived at the 
Central Animal Laboratory 2 weeks before the start of experiments. They were held 
at a specific pathogen-free unit in filter-top cages with sterilized sawdust. Food 
(Hope Farms, Woerden, The Netherlands) and acidified water were supplied ad 
libitum. The temperature was kept at 20-24°C, with a relative humidity of 50% to 
60%, 15 air changes/h and light and dark periods of 14 and 10 h, respectively. All 
experiments were approved by the Ethics Committee on animal experiments of the 
University Medical Centre Nijmegen (18 march 2002, registration number KUNDEC 
2002-25). 
Induction of neutropenia and anaesthesia 
On day -4, mice received cyclophosphamide (Endoxan-ASTAR; Dagra, Diemen, The 
Netherlands) 150 mg/kg subcutaneously to induce neutropenia. On day -1, a second 
dose of 100 mg/kg cyclophosphamide was given.27,28 Leucocyte counts confirmed a 
neutropenia of <0.1 x 106 leukocytes/L. During injections, infusions and blood 
collection, mice received inhalation anaesthesia with isoflurane. Body temperature 
was regulated by a heating mattress. 
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Microorganisms 
Escherichia coli strain ATCC 25922 (Rosco Diagnostica, Taastrup, Denmark) was 
used. MICs for ceftazidime and meropenem were 0.25 and 0.025 mg/L respectively, 
as determined by Etest and microdilution methods. Pseudomonas aeruginosa strain 
ATCC 27853 was used, with MICs of 1 mg/L for ceftazidime and meropenem. Bacte-
ria were stored at -80°C and subcultured on blood agar 2 days before the experi-
ment. Subsequently, overnight cultures were prepared by inoculation of two colonies 
in 10 mL of Mueller-Hinton broth. On test days, 2 h prior to inoculation, bacteria 
were diluted and resuspended in fresh Mueller-Hinton broth. At t = -2 h, a standard-
ized inoculum was injected into the left thigh muscle of each mouse.29-31 
Antibiotics 
Ceftazidime (GlaxoSmithKline B.V., Zeist, The Netherlands), with a dose-dependent 
affinity for PBP-3 and -1, and meropenem (AstraZeneca, Zoetermeer, The Nether-
lands), with a non-dose related high affinity for PBP-2 and low affinity for PBP-3, 
were used.32 A stock solution of each antibiotic of 5 mg/mL was divided into pyro-
gen-free Eppendorf tubes, stored at -80°C and used for all experiments. Thirty 
minutes before each experiment, one tube was defrosted and diluted in sterile 0.9% 
NaCl to the desired concentrations. In continuously treated mice, an intravenos (iv) 
cannula (Neoflon 0.7 x 19 mm, 24 gauche; Becton Dickinson Infusion Therapy AB, 
Helsingborg, Sweden) was inserted into the tail vein at t = 0 h. In the bolus group an 
iv injection was given in the tail vein at t = 0 h. 
Blood and tissue collection and bacterial counts 
Blood samples from the retro-orbital plexus were collected in sterile pyrogen-free 
Falcon tubes (Becton Dickinson, Franklin Lakes, NJ, USA), containing 10 μL of a 
pyrogen-free heparin solution containing 5000 U of heparin/mL (Leo Pharmaceutical 
Products B.V., Weesp, The Netherlands), immediately stored on ice and centrifuged 
at 500 g for 5 min to obtain plasma samples. Plasma (100 μL) was diluted in 900 μL 
of 0.9% NaCl for endotoxin assays. Undiluted plasma samples were stored in sterile 
Eppendorf tubes at -80°C until assays were performed. Liver, spleen and thigh 
muscles were removed aseptically, immersed in saline, weighed and homogenized in 
a sterilized tissue grinder. Serial dilutions of homogenized tissues were plated on 
sheep blood agar. After overnight incubation at 37°C, cfu counts were performed 
and expressed as numbers of cfu/liver, cfu/spleen and cfu/g muscle. 
Bacterial morphology 
Bacterial morphology was judged by one of the investigators and a pathologist on 
haematoxylin-eosin-stained histological sections of thigh muscles, using light micros-
copy with a magnification of 400 x and 1000 x. Bacteria were defined as filaments 
when a length of 3 bacilli or more was observed. 
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Figure 1. Filaments in thigh muscle (HE-stained) 
Full colour illustration on page 133 
 
Endotoxin and cytokine assays 
Endotoxin concentrations of plasma were measured with a chromogenic limulus 
amoebocyte lysate (LAL) assay (Associates of Cape Cod Inc., Falmouth, MA, USA) 
according to the instructions of the manufacturer. Measurement of plasma TNF-α 
concentrations was performed by radioimmunoassay.33 IL-6 concentrations were 
determined in plasma by ELISA (Biosource International, Camarillo, CA, USA). Detec-
tion limits of the cytokine assays were 40 pg/mL and 150 pg/mL, respectively. 
Pharmacokinetics 
Plasma concentrations of ceftazidime were checked by HPLC.34,35 For the HPLC 
assay, a Shimadzu with UV/Vis detector was used; flow 1.0 mL/min, pressure ± 120 
bar. The method was linear over the dosing range studied, the lowest level of detec-
tion 0.1 mg/L, the intra- and inter-assay variance of measurements 1.1% to 3.8% 
(performed in triplicate on separate days) and spike recovery 98%. Pharmacokinetic 
parameters were calculated using the Winnonlin program (Pharsight Corp., Mountain 
view, CA, USA). The Akaike value was used as parameter to choose the best model 
describing these results. 
Statistical Analysis 
Statistical analysis was performed using the SPSS package for Windows (SPSS 10.0, 
Chicago, IL, USA) and GraphPad Prism 3.0 (GraphPad software Inc., San Diego, CA, 
USA). Normal distribution was checked by Levene’s test for equality of variances. 
Differences in viable counts and endotoxin and cytokine concentrations were ana-
lysed by multivariate analysis (ANOVA) for normally distributed parameters, followed, 
when appropriate, by post hoc t-tests. Parameters without a normal distribution were 
analysed with the non-parametric Kruskal-Wallis test, followed by the Mann-Whitney 
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test to investigate differences among groups. Correlations among parameters were 
determined with the Pearson correlation test or Spearman’s rank correlation test. 
Statistical tests were considered significant at p<0.05. 
Outline of the studies 
Control studies 
Baseline pharmacokinetics of a bolus injection of ceftazidime 80 mg/kg iv was 
documented in a group of 14 mice. After injections, at t = 1, 5, 10, 20, 30, 40 and 
60 minutes, plasma samples were collected. Pharmacokinetic differences between 
infected and non-infected mice were determined in 36 neutropenic mice during 
continuous and intermittent schedules. 
The course of parameters during untreated E. coli sepsis, was separately studied in 
10 mice. To evaluate effects of anaesthesia, injections and the presence of an 
infusion cannula on release of cytokines, a sham experiment was performed in 18 
mice, receiving only saline as inoculum and saline treatments. 
Main experiments: continuous versus intermittent dosing schedules of ceftazidime in 
E. coli sepsis 
In seven experiments, a total of 83 neutropenic mice were challenged with 1 x 107 
cfu of E. coli. Two h after inoculation, mice received injections or continuous infu-
sions of ceftazidime. In continuously treated mice, 20% was administered as a 
loading dose, and the remaining 80% was infused by a Terofusion syringe pump, 
model STC-521, during the next 4 h. Experiments were performed with 10, 20, 40 
and 80 mg/kg ceftazidime (0.25, 0.50, 1.0 and 2.0 mg/mouse). Experiments with 40 
and 80 mg/kg were performed twice. In mice treated with 20 mg/kg and 80 mg/kg 
ceftazidime, endotoxin assays were performed, comparing the highest dose-level 
with lower doses. In a 80 mg/kg ceftazidime experiment, the time-course of cytokine 
concentrations was also studied. 
To check whether changes in cytokine patterns during continuous and intermittent 
schedules are unique for the combination of E. coli and ceftazidime, comparison 
studies of meropenem and ceftazidime were added in infections with E. coli or P. 
aeruginosa at various concentrations. 
Because the MIC of meropenem for E. coli is 10-fold lower, compared with that of 
ceftazidime, the dose of meropenem was adjusted in the E. coli experiments. For P. 
aeruginosa, MICs of both antibiotics are comparable, so equal doses could be ap-
plied. 
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Results 
Morphology and bacterial counts 
Continuous infusion of 80 mg/kg ceftazidime was the lowest dose preventing fila-
ment formation in E. coli infections. Morphological studies showed bacterial debris 
and bacilli. In all other groups, including mice treated with bolus injections of 80 
mg/kg ceftazidime, large filaments were seen (Fig 1.). Meropenem induced sphero-
plast formation in all regimens in both infections. 
 
 
 
 
Figure 2. Cfu of E.coli in thigh muscles at t =4 h after continuous or bolus injection of ceftazidime at various 
concentrations 
 
 
 
In the E. coli experiments, mean values of muscle cfu/g were 1.7 x 109 (SD 1.1 x 
109) and 5.4 x 107 (SD 4.3 x 107), respectively (p <0.001), for untreated and treated 
E. coli infections at t = 4 h. Cfu in muscle at t = 4 h did not differ between treatment 
regimens or antibiotic dose levels (Fig 2.). Cfu counts in liver and spleen of antibiotic-
treated mice were significantly correlated (r = 0.995, p = 0.0001). Cfu in muscles of 
treated mice were negatively correlated with IL-6 concentrations (r = –0.579, p = 
0.007). 
Varying antibiotic type in these E. coli experiments revealed the following results. Fig 
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ceftazidime continuously (1.5 x 108 versus 2.8 x 106, p = 0.009). In the Pseudomo-
nas experiments, lower cfu counts were shown during continuous treatment with 
either ceftazidime or meropenem, especially at doses of 320 mg/kg (p = 0.083 for 
ceftazidime, p = 0.05 for meropenem) (Fig 4.). 
During untreated E. coli sepsis, cfu in thigh muscle rose from 1.64 x 107 at t = -2 h 
to 4.8 x 109 at t = 4 h. Cfu in liver and spleen rose from 0 at t = -2 h to 2.1 x 106 
and 3.4 x 104, respectively, at t = 4 h (Fig 5.). Cfu counts in muscle and liver (r = 
0.707, p = 0.022), muscle and spleen (r = 0.869, p = 0.001) and spleen and liver (r 
=0.867, p = 0.001) were significantly correlated. 
 
 
 
 
Figure 3. Muscle cfu of E. coli, plasma TNF-α and IL-6 after 4 h of treatment with ceftazidime or meropenem 
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Figure 4. Plasma IL-6 during P. aeruginosa sepsis after 4 h of treatment with 160 mg/kg or 320 mg/kg 
ceftazidime or meropenem. Cfus in thighs after 320 mg/kg 
 
 
 
Figure 5. Plasma cytokines and cfu during 4 h of untreated E. coli sepsis (inoculation at t = -2 h) 
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Endotoxin 
Regardless of morphology, plasma endotoxin concentrations showed no differences 
between mice with a continuous or a bolus regimen of 80 mg/kg (Table 1.). In the 
experiment with 20 mg/kg ceftazidime, plasma endotoxin levels were significantly 
higher in both bolus and continuous treatment groups, compared with non-treated 
controls (p = 0.048 and p = 0.008, respectively). With regard to endotoxin levels, 
bolus treatment did not differ from continuous treatment. 
Cytokines 
Plasma TNF-α and IL-6 concentrations were below the detection limits at t = 0.1, 
0.5, 1, 2 and 4 h in all saline experiments. Cytokine concentrations declined during 
the natural course of infection (Fig 5.). Spleen cfu were negatively correlated with IL-
6 concentrations (r = -0.818, p = 0.004). At all concentrations of ceftazidime, plasma 
IL-6 levels were higher during continuous infusions (mean 14 261 pg/mL, SD 7578), 
compared with bolus-treated (mean 3563 pg/mL, SD 3263) and untreated mice 
(mean 2810 pg/mL, SD 2295) in E. coli sepsis (Table 1.). P values were < 0.0001 for 
the difference between continuous-treated mice and both bolus-treated and un-
treated mice. Mean IL-6 concentrations at 10, 20, 40 and 80 mg/kg dose levels were 
15 268 pg/mL, 18 418 pg/mL, 9728 pg/mL and 13 840 pg/mL for continuous treat-
ments and 2250 pg/mL, 3843 pg/mL, 3565 pg/mL and 2072 pg/mL for bolus treat-
ments, respectively. P values for the difference between both treatments at each 
dose level were 0.140, 0.037, 0.326 and 0.001, respectively. At 80 mg/kg, continu-
ous dosing also caused higher TNF-α concentrations (596 pg/mL) than bolus dosing 
did (97 pg/mL) (p = 0.017). Plasma TNF-α and IL-6 were significantly correlated (r = 
0.698, p = 0.006). 
Monitoring plasma cytokine concentrations for 4 h of treatment with 80 mg/kg 
ceftazidime revealed that at t = 0, 1, 2 h, cytokines did not differ, reaching signifi-
cant higher concentrations of IL-6 in continuously treated animals, compared with 
bolus treatment at t = 4 h. Plasma TNF-α showed an early peak, with declining 
values after t = 0.5 or 1 h for bolus or continuous treatment, respectively (Fig 6.). 
Plasma IL-6 levels demonstrated remarkable overlap with plasma ceftazidime con-
centrations in continuous- and bolus-treated mice. 
Varying antibiotic type in E. coli experiments revealed that IL-6 and TNF-α responses 
were significantly higher in continuously treated mice (p < 0.05 for ceftazidime and 
meropenem) (Fig 3.). Cytokine responses after continuous and bolus antibiotic 
treatment of Pseudomonas infections were comparable to those in E. coli infections 
(Fig 4.). Higher doses of continuously given ceftazidime caused more pronounced IL-
6 [mean 3538 pg/mL (SD 2029) for 320 mg/kg and 930 pg/mL (SD 499) for 160 
mg/kg, p = 0.02] and TNF-α responses (mean 285 (SD 122) for 320 mg/kg and 48 
(SD 15) for 160 mg/kg, p = 0.018). Using higher concentrations of meropenem 
continuously (320 mg/kg), higher cytokine concentrations were induced compared 
with the lower dose of 160 mg/kg (for IL-6, p 0.083; for TNF-α, p = 0.020). Bolus 
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treatment with ceftazidime showed no dose-dependent IL-6 response in contrast to 
bolus meropenem (p 0.003). 
 
 
Table 1. Endotoxin, TNF-α and IL-6 in E. coli sepsis, after 4 h of continuous or bolus treatment at various 
dose levels (ND= not determined) 
Dose level Continuous versus 
intermittent (n) 
Mean plasma endotoxin 
(SD) U/mL 
Mean plasma TF-α (SD) 
pg/mL 
Mean plasma IL-6 
(SD) pg/mL 
     
80 mg/kg continuous (6) 1706 (214) 596 (402) 13 840 (5736) 
80 mg/kg bolus (6) 1719 (381) 97 (116) 2072 (980) 
controls bolus saline (3) 1734 (101) 160 (208) 3233 (3860) 
     
40 mg/kg continuous (6) ND ND 9728 (7336) 
40 mg/kg bolus (4) ND ND 3565 (672) 
controls bolus saline (2) ND ND 1535 (502) 
     
20 mg/kg continuous (4) 2812 (173) 250 (100) 18 418 (8697) 
20 mg/kg bolus (4) 3370 (700) 278 (155) 3843 (693) 
controls bolus saline (3) 1165 (120) 220 (34) 2915 (1364) 
     
10 mg/kg continuous (3) ND 295 (90) 15 268 (9433) 
10 mg/kg bolus (3) ND 200 2250 (325) 
controls bolus saline (2) ND 200 3880 
 
 
Pharmacokinetics of ceftazidime 
After 80 mg/kg iv, mean plasma peak levels of ceftazidime were 486 (SD 69.5) mg/L 
and plasma half-life was 10.8 min. Mean plasma concentration of ceftazidime at t = 
4 h during continuous infusion of 80 mg/kg in infected mice was 67.6 mg/L (SD 
41.7). A comparison of infected and non-infected mice revealed 30.1% lower mean 
plasma concentrations of ceftazidime in infected mice (p = 0.24). One h after bolus 
injections, mean plasma concentrations of ceftazidime were 3.0 (SD 0.849) and 8.75 
mg/L (SD 1.202) for infected and non-infected mice respectively (p = 0.031). At t = 
2 h, plasma concentrations were undetectable in both infected and non-infected 
mice. 
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Figure 6. Course of cytokine concentrations during 4 h of sepsis-treatment with ceftazidime 80 mg/kg iv  
 
Discussion 
The present study on the influence of antibiotic type and dosing regimen on bacterial 
morphology, endotoxin release and cytokine response in murine sepsis shows a 
remarkable dependence of cytokine response on antibiotic treatment regimen: 
continuous antibiotic dosing causes higher cytokine levels, even at very low antibiotic 
concentrations. For E. coli, we titrated continuous dosing levels of ceftazidime to a 
cut-off point of 80 mg/kg at which induction of filaments could be prevented. Bolus 
treatment with the same dose never did prevent filament formation even with very 
high peak levels. To our knowledge, this is the first study demonstrating these 
relations in-vivo between bacterial morphology and type of antibiotic dosing sched-
ule. 
Using continuous dosing schedules, cytokine release was positively correlated to 
antibiotic dose. 
Since cfu counts showed an inverse relationship with plasma IL-6 concentrations, 
suggesting more effective bacteriolysis, continuous infusion at higher concentrations 
of antibiotics might be more effective in sepsis treatment. This finding corresponds to 
our previous in-vitro findings, showing increased bacteriolysis of E. coli or P. aerugi-
nosa exposed to continuous concentrations of ceftazidime at high concentration 
levels of 40 x MIC and up.23 
Efficacy of treatment with ß-lactam antibiotics has been shown to depend on the 
time above MIC.36-38 In our model, plasma IL-6 levels corresponded to antibiotic 
concentration levels and are negatively correlated with muscle cfu, suggesting that 
IL-6 is useful as parameter of bacterial killing, especially in the initial phase of treat-
ment, when bacterial counts are still high and variable. In murine sepsis, Remick et 
al.39 demonstrated a clear relationship of initial high IL-6 concentrations and mortal-
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ity, whereas Pallua and von Heimburg40 showed that IL-6 in contrast to TNF-α shows 
significant elevations after LPS exposure. Both studies correspond to our findings. 
Our study has several limitations. Bacterial counts are not reliable as parameters of 
bacterial load when morphological changes are present, as one filament is counted 
only as one cfu, but represents a large source of endotoxin.23 We were also unable 
to demonstrate a relation between circulating endotoxin levels and bacterial mor-
phology or treatment regimen. Clearance from the circulation, adherence of en-
dotoxin molecules to tissue and plasma components, as well as retainment in the 
bacterial cell wall at the infection site may explain this finding. Vianna et al.41 also 
showed increased IL-6 responses without differences in plasma endotoxin concentra-
tions during treatment of murine sepsis. In addition, the amount of endotoxin cannot 
be measured at the site of infection by LAL assays, as shown in our earlier studies.16 
Thus, plasma endotoxin is an indirect parameter, not adequately representing sepsis 
severity. Direct assays using PCR may enable direct quantification of bacterial and 
endotoxin load. 
We conclude that antibiotic dosing regimen in sepsis has important consequences for 
bacterial morphology and cytokine response, particularly in the initial hours of 
therapy. High and continuous dosing schedules appear most advantageous in terms 
of bacteriolysis and cytokine responses. Future studies should extend these findings 
to human infections and explore whether alterations in bacterial morphology and 
subsequent enhancement of endotoxin release are related to cytokine responses and 
whether alternative dosing schedules alter the clinical course of sepsis. 
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Abstract 
Objectives: Treatment of Gram-negative infections with Penicillin Binding Protein 
(PBP)-3 specific ß-lactam antibiotics induces bacterial filaments, containing excessive 
amounts of endotoxin, which is the key-mediator in the pathogenesis of sepsis. We 
hypothesize, that filament lysis in-vivo may cause severe sepsis symptoms by en-
hancement of endotoxin-induced pro-inflammatory responses. We studied the effects 
of exposure of ceftazidime-induced filaments to ß-lactams or an aminoglycoside in 
murine sepsis. 
Methods: Ceftazidime was administered either continuously or by bolus injections in 
septic neutropenic mice, to prevent or induce E. coli filaments, respectively. Subse-
quently, filaments or normal bacilli were exposed to meropenem, ceftazidime, tobra-
mycin or saline. After 0.5 to 4.0 h, morphology, cfu, plasma endotoxin, TNF-α, and 
IL-6-concentrations were determined. 
Results: During treatment with ceftazidime continuously rod-shaped bacilli and high 
cytokine concentrations were shown. Subsequent injection of meropenem caused a 
rise of cytokine concentrations, compared with mice with intramuscular filaments (p 
0.001 for TNF-α and IL-6). 
Mice with filaments exposed to a second gift of ceftazidime, showed elongation of 
filaments, accompanied by elevation of circulating IL-6 concentrations (p 0.034). 
Conclusions: During continuous infusions, cytokines are high, especially after addi-
tional treatment with meropenem, reflecting efficient bacterial lysis, without filament 
formation. Exposure of E. coli filaments to meropenem causes lower cytokine re-
sponses, suggesting less successful bacteriolysis. However, filaments exposed to a 
second gift of ceftazidime become longer and induce more cytokines compared with 
short filaments. Our results suggest that endotoxin may be preserved within bacterial 
filaments, which may be , at least initially, protected against lysis by meropenem. 
This may induce the risk a postponed, but aggravated endotoxin release during 
subsequent antibiotic therapy. 
Introduction 
Sepsis is a serious life threatening condition with a mortality between 18-56%.1,2 
Gram-negative bacteria are causative in 20% of cases.3 The most crucial mediator in 
the pathogenesis of Gram-negative sepsis and its inflammatory response is endotoxin 
(lipopolysaccharide, LPS).4-8 Exposure to endotoxin leads to production of pro-
inflammatory cytokines, like TNF-α or interleukin(IL)-6 by host cells. Concentrations 
of endotoxin and cytokines are closely correlated.9-12 
Bacterial endotoxin release during treatment with ß-lactam antibiotics depends on 
the PBP-binding characteristics of the antibiotic.13-15 PBPs are enzymes, anchored in 
the cytoplasmic membranes of bacteria, which have significant biological functions, 
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including roles in determination of cell shape, induction of capsule synthesis, and 
regulation of autolysis.16 Exposure to low concentrations or short peak concentrations 
of ceftazidime causes PBP-3 inhibition, disabling bacterial septation capacity and 
thereby leading to growth in filamentous forms.13-17 In-vitro, filaments cause high 
endotoxin releases18,19 and induce high levels of TNF-α and IL-6 produced by mono-
cytes.20 On the other hand, meropenem, which inhibits PBP-2, causes formation of 
large rounded cells, called spheroplasts.18,21,22 These spheroplasts do not release 
high amounts of endotoxin in-vitro.12,18 
Recently, we demonstrated that continuous treatment of septic mice with at least 80 
mg/kg ceftazidime prevents filament formation, which is associated initially with 
higher cytokine responses due to rapid lysis of bacteria.17 
Sixty years ago, reports were published on clinical deterioration of patients shortly 
after the start of antibiotic therapy. This observation was attributed to exaggerated 
inflammatory reactions due to high endotoxin releases.23-26 Despite of this observa-
tion, early and effective treatment, preventing severe inflammation and concomitant 
signs of organ dysfunction, seems to be essential. 
We hypothesize that filament induction during initial treatment of sepsis may induce 
severe sepsis symptoms by enhancement of endotoxin-induced pro-inflammatory 
responses. The present studies investigate the effects of subsequent gifts of several 
types of antibiotic in mice with E. coli sepsis, in which bacterial filaments are already 
present. In clinical practice this situation occurs when bacteria are exposed to a 
second gift of the same antibiotic or when monotherapy is changed to combination 
therapy. 
Materials and methods 
Mice 
Female outbred Swiss mice (aged 6 to 8 weeks, weight 20-30 g), were used in all 
studies. Mice were bred by Harlan (Horst, The Netherlands) and arrived at the 
Central Animal Laboratory two weeks before the start of experiments. They were 
held at a specific pathogen-free unit in filter-top cages with sterilized sawdust. Food 
(Hope Farms, Woerden, The Netherlands) and acidified water were supplied ad 
libitum. Temperature was kept at 20-24°C, with a relative humidity of 50 to 60%, 15 
airchanges/h, light and dark periods of 14 and 10 h, respectively. All experiments 
were approved by the ethical committee on animal experiments of the University 
Medical Centre Nijmegen (18 March 2002, registration number KUNDEC 2002-25). 
Induction of neutropenia and anaesthesia 
On day -4, mice received cyclophosphamide (Endoxan-ASTAR , Dagra, Diemen, The 
Netherlands) 150 mg/kg subcutaneously to induce neutropenia. On day -1, a second 
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dose of 100 mg/kg cyclophosphamide was given.27,28 Leucocyte counts confirmed a 
neutropenia of <0.1 x 106 leukocytes/L. During injections, infusions, and blood 
collection mice received inhalation anaesthesia with isoflurane. Body temperature 
was regulated by a heating mattress. 
Micro-organisms 
E. coli strain ATCC 25922 (Rosco Diagnostica, Taastrup, Denmark) was used in all 
experiments. MICs for ceftazidime, meropenem and tobramycin were 0.25 mg/L, 
0.025 mg/L and 0.5 mg/L, respectively, as determined by Etest and microdilution 
methods. Bacteria were stored at -80°C and subcultured on blood agar two days 
before the experiment. Subsequently, overnight cultures were prepared by inocula-
tion of two colonies in 10 mL Mueller-Hinton broth. On test days, 2 h prior to inocula-
tion, bacteria were diluted and resuspended in fresh Mueller-Hinton broth. At t = -2 
h, a standardized inoculum of 1 x 107 cfu was injected into the left thigh muscle of 
each mouse. 
Antibiotics 
Ceftazidime (GlaxoSmithKline B.V., Zeist, The Netherlands), with a dose-dependent 
affinity for PBP-3 and -1, meropenem (AstraZeneca, Zoetermeer, The Netherlands), a 
carbapenem with a non-dose-related high affinity for PBP-2 and a low affinity for 
PBP-3,29 and the aminoglycoside tobramycin were used. A stock solution of each 
antibiotic of 5 mg/mL was divided in pyrogen free Eppendorf tubes, stored at -80°C 
and used for all experiments. Thirty minutes before each experiment, one tube was 
defrosted and diluted in sterile NaCl 0.9% to the desired concentrations. In continu-
ously treated mice, an intravenous(iv) cannula (Neoflon 0.7 x 19 mm, 24 gauche, 
Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden) was inserted into the 
tail vein at t = 0 h. Subsequently, a loading dose of 0.1 mL was administered, 
followed by an infusion rate of 0.1 mL/h, using a ceftazidime solution containing 4 
mg/mL. The infusion rate was regulated by a Terofusion syringe pump (model STC-
521). In bolus treated mice, injections of 0.1 mL of a solutions containing ceftazidime 
20 mg/mL were administered at t = 0 h. In both groups, 0.1 mL of a solution of 
meropenem containing 60 mg/mL was administered at t = 4 h. 
Blood and tissue collection and bacterial counts 
Blood samples from the retro-orbital plexus were collected in sterile pyrogen-free 
Falcon-tubes (Beckton Dickinson, Franklin Lakes, NJ, USA), containing 10 μL of a 
pyrogen-free heparin solution containing 5000 U/mL (Leo Pharmaceutical Products 
BV, Weesp, The Netherlands), immediately stored on ice and centrifugated at 500 g 
for 5 min to obtain plasma samples. Plasma (100 μL) was diluted in 900 μL of 0.9% 
NaCl for endotoxin assays. Undiluted plasma samples were stored in sterile Eppen-
dorf tubes at -80°C until assays were performed. Liver, spleen and thigh muscles 
were removed aseptically, immersed in saline, weighed and homogenized in a 
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sterilized tissue grinder. Serial dilutions of homogenized tissues were plated on sheep 
blood agar. After overnight incubation at 37°C, cfu counts were performed and 
expressed as numbers of cfu/g tissue. 
Bacterial morphology 
Bacterial morphology was judged by one of the investigators and by a pathologist on 
haematoxylin-eosin-stained histological sections of thigh muscles, using light micros-
copy with a magnification of 400 x and 1000 x. Bacteria were defined as short 
filaments when a length of 3-10 rods was observed. Long filaments were defined as 
bacteria longer than 10 rods. Investigators were blinded for types of treatment. 
Endotoxin and cytokine assays 
Plasma endotoxin concentrations were measured with a chromogenic limulus amoe-
bocyte lysate (LAL) assay (Associates of Cape Cod Inc., Falmouth, MA, USA) accord-
ing to the prescriptions of the manufacturer. The detection limit of the assay was 100 
U/mL. Measurement of plasma TNF-α concentrations was performed by radioimmu-
noassay.30 IL-6 concentrations were determined in plasma by ELISA Biosource 
International, Camarillo, CA, USA). Detection limits of the cytokine assays were 20 
and 150 pg/mL, respectively. 
Statistical Analysis 
Statistical analysis was performed using the SPSS package for Windows (SPSS 10.0, 
Chicago, IL, USA) and GraphPad Prism 3.0 (GraphPad software Inc., San Diego, CA, 
USA). Normal distribution was checked by Levene’s test for equelity of variances. 
Differences in viable couts and endotoxin and cytokine concentrations were analysed 
by multivariate analysis (ANOVA) for normally distributed parameters, followed, when 
appropriate, by post hoc t-tests. Parameters without a normal distribution were 
analysed with the non-parametric Kruskal-Wallis test, followed by the Mann-Whitney 
test to investigate differences among groups. Correlations among parameters were 
determined with the Pearson correlation test or Spearman’s rank correlation test. 
Statistical tests were considered significant at p< 0.05. 
Outline of the studies 
Short term effects of antibiotics on bacterial filaments 
To study the short term effects of exposure of filaments to further antibiotic therapy, 
two experiments were performed in 22 mice. After inoculation of E. coli in murine 
thigh muscles at t = -2 h, filaments were induced by administration of ceftazidime 
bolus 20 mg/kg iv at t = 0 h. At t = 4 h, either a bolus saline, a bolus ceftazidime (20 
mg/kg) or a bolus tobramycin (10 mg/kg) was administered iv. At t = 4½ and t = 5 
h mice were sacrificed for morphological studies, cfu counts, plasma endotoxin, and 
cytokine concentrations. 
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Ceftazidime-meropenem studies 
In two further experiments, effects of additional antibiotic therapy on inflammatory 
responses in septic mice with and without filamentous bacilli was studied in 36 mice. 
At t = -2 h mice received an inoculum of E. coli in the left thigh muscle. At t = 0 h, 
mice were treated with either bolus injections or continuous infusions of ceftazidime 
80 mg/kg to obtain septic mice with and without intramuscular filaments, respec-
tively.17 
At t = 4 h, mice of both groups were treated with meropenem 240 mg/kg. At t = 0, 
4, 6 and 8 h mice were sacrificed for cfu counts and determiniation of cytokine 
concentrations. 
Results 
Short term effects of antibiotics on bacterial filaments 
Thirty min and 1 h after a second antibiotic dose or saline, filaments were still 
present in treatment groups and controls, although filaments were shorter (3-10 
rods) in tobramycin-treated mice (Fig 1.), compared with twice ceftazidime- (>10 
rods, Fig 1.) or saline-treated mice (>10 rods). 
Figure 1.  
A. Short filaments (3-10 rods) after exposure of ceftazidime-induced filaments to tobramycin 
B. Long filaments (>10 rods) after exposure of ceftzidime-induced filaments to a second dose 
of ceftazidime 
Full colour illustration on page 133 
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Cfu in thigh muscles were lower in tobramycin and 2x ceftazidime-treated mice 
compared with saline-treated mice (p 0.005 for both groups versus saline treatment, 
Fig 2.). Liver and spleen cfu significantly correlated in each mouse (p< 0.0001), but 
did not differ between groups. 
Thirty minutes after the second dose of ceftazidime, plasma IL-6 concentrations were 
significantly elevated in mice with filaments exposed to another gift of ceftazidime, 
compared with mice with filaments receiving saline (p 0.034). IL-6 and TNF-α con-
centrations in tobramycin-treated mice did not differ from controls or ceftazidime 
treatment. One h after the second dose the same patterns were shown, though 
differences were not significant (Fig 2.). Plasma endotoxin concentrations did not 
differ between groups (Fig 2.). 
 
 
 
Figure 2. Cfu in thigh muscle, plasma IL-6- and endotoxin-concentrations in mice with intramuscular E.coli
filaments exposed to saline, tobramycin or ceftazidime 
 
 
Ceftazidime-meropenem studies 
At t = 0 h, two hours after inoculation with E. coli, cytokine concentrations were 
already grossly elevated (Fig 4. and 5.). After 4 h of ceftazidime continuously iv, 
bacteria in the thigh muscle showed rod-shapes and debris, while mice treated with 
a bolus injection of ceftazidime contained intramuscular filaments. Cfu did not differ 
between groups with or without filaments, though mice without filaments showed 
significant higher cytokine concentrations at t = 4 h (p 0.05 for IL-6, Fig 4. and 5.). 
After a bolus injection of ceftazidime 80 mg/kg, mean plasma antibiotic peak levels 
were 486 mg/L (SD 69.5). Plasma half-life (T½) was 10.8 min. Four h after bolus 
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injections, plasma ceftazidime concentrations were undetectable. Mean plasma 
concentrations during continuous infusion of ceftazidime were 67.6 mg/L (SD 41.7). 
When continuous infusion is stopped, plasma concentrations are expecteded to 
decline below MIC levels after 84.4 min (8 x T½) 
 
 
 
Figure 3. Muscle cfu in mice with E. coli bacilli (rods) or E. coli filaments, 
before and after addition of meropenem iv 
 
 
During further therapy, muscle cfu showed a decline after meropenem injections in 
mice pretreated with ceftazidime continuously (mice without filaments) (p 0.043, Fig 
3.), which was accompanied by elevations of circulating TNF-α and IL-6 (p 0.001 for 
both cytokines at t = 6 h). At t = 8 h cytokine concentrations declined, but showed 
still a trend of higher concentrations compared with mice with filaments (p 0.083 for 
IL-6). Within the group of mice pretreated with ceftazidime bolus (i.e. mice with 
filaments), cfu did not decline significantly in the first 2 h after administration of 
meropenem (p 0.063, Fig 3.) and concentrations of both cytokines remained low (Fig 
4. and 5.). 
IL-6 and TNF-α showed a strong correlation: p 0.0001, r = 0.704. There was no 
significant correlation between cfu and both cytokines. 
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Figure 4. Plasma TNF-α concentrations (mean, SD) in mice with E. coli
rods or E. coli filaments, both treated with meropenem at t = 4 h 
 
 
 
Figure 5. Plasma IL-6 concentrations (mean, SD) in mice with E.coli rods 
or E.coli filaments, both treated with meropenem at t = 4 h 
 
Discussion 
The present study in mice shows that treatment with a single dose of ceftazidime 
easily induces filament formation in-vivo. A second gift of ceftazidime leads to further 
elongation of filaments, accompanied by rising circulating cytokine concentrations, 
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while exposure of filaments to tobramycin leads to shortening of filaments, accom-
panied by declining cytokines. Our results suggest that ceftazidime treatment of 
filamentous bacteria leads to enhanced exposure of the host to toxic bacterial prod-
ucts, which can be disadvantageous for the host. 
Continuous infusion of ceftazidime (80 mg/kg) prevents filament formation, which is 
accompanied by initial high concentrations of circulating IL-6 and TNF-α, compared 
with mice with intramuscular filaments (Fig 4. and 5.).17 In previous in-vitro studies, 
we showed that imipenem, a PBP-1-specific antibiotic, induced a quick bacterial lysis 
without morphological changes, which was also related to high initial endotoxin-
releases.18 In the same in-vitro study, filament-inducing agents initially liberated low 
amounts of endotoxin, and turned out to contain larger amounts of cell bound 
endotoxin preserved within the cell wall. In the first part of the present in-vivo study, 
circulating endotoxin did not differ between groups, while cytokines were higher in 
mice with the largest filaments. This observation can be explained by clearance of 
endotoxin from the circulation, adherence of endotoxin molecules to tissue and 
plasma components or retainment of endotoxin in the bacterial cell at the site of 
infection. We conclude that, though in-vitro studies of endotoxin release by various 
forms of bacteria show clear results, plasma endotoxin concentrations are not 
representative for the amount of endotoxin present at or fliberated from the infection 
site.12,17 Addition of a ß-lactam with a different PBP-affininity (meropenem), led to 
significant elevations of plasma cytokines in mice with rods and bacterial debris, 
which was accompanied by a significant decline of cfu. In mice with filaments how-
ever, circulating cytokines remained low during meropenem exposure, reflecting a 
lower exposure of the host to toxic bacterial products like endotoxin, probably by less 
effective bacterial killing during the study period. Though cfu counts in mice with 
filaments appear to be lower (Fig 3.) than in mice with rods, it has to be emphasized 
that one bacterial filament is counted as only one cfu, but still represents a large 
biomass and large numbers of endotoxin molecules.14,18-20,31 Thus it is tempting to 
assume that toxic bacterial products, like endotoxin, can be retained within filaments 
at the site of infection, even during treatment periods of at least 8 h. 
There are several explanations for our finding that meropenem was not able to break 
filaments and liberate endotoxin within the study period. First of all, this may be due 
to inability of meropenem to reach the filaments at the infectious focus. Also the 
drug may not be able to reach or inhibit the receptors (PBP-2) on cytoplasmic mem-
branes of filaments. Another explanation may be that, unexpectedly, rods contain 
more endotoxin than filaments, in contrast to in-vitro findings. The timing of the 
second dose may also influence the results: when administered too late, mice suffer 
from severe sepsis, with irreversible sequelae. Finally other factors than filament lysis 
can may be confounders, influencing TNF-α and IL-6 concentrations. 
Our study has some limitations: 
1. Due to severe sepsis and short survival, the period of observation was limited. A 
model of less severe infection should be investigated to approach this problem. 
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2. The measurement of cfu is posing a technical problem, as one cfu may either 
reflect a single rod or a long filament with a lot of biomass.17,31 To solve this problem 
newer techniques to quantify bacterial biomass are needed. 
On the basis of these data, we believe that the choice of antibiotic type or dosing 
regimen is essential during the initial stage of sepsis treatment. Filament induction is 
disadvantageous by the potency of more endotoxin-release and subsequent exag-
gerated inflammatory responses.12,32-34 Whether high cytokine responses are favour-
able or not is still a matter of discussion.25 Continuous dosing schedules of ß-lactam 
antibiotics may be favourable with respect to filament prevention, despite of intial 
higher cytokine responses, which may be associated with clinical effects. This study 
shows that, at least initially, filaments seem to be resistant against lysis during 
subsequent exposure to a ß-lactam antibiotic with a different PBP-affinity. This 
resistance may lead to delayed and unexpected LPS-releases when filament lysis is 
finally achieved. 
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Summary 
 
Antibiotics are the most important therapeutic tools in the medical therapy of bacte-
rial infections. However, shortly after their introduction, observations of severe 
clinical deterioration of the host occurring shortly after commencing antibiotic ad-
ministration were published. Several years later, it became clear that this phenome-
non was related to an antibiotic-induced release of toxic bacterial products, especially 
endotoxin or lipopolysaccharide (LPS). During the last century, the composition of 
this molecule and much of its working mechanism has been elucidated. In chapter 
2 a short overview is presented, explaining the most important biological mecha-
nisms of LPS-toxicity. During normal bacterial growth, LPS-molecules are released by 
bacteria in small amounts. However, after exposure to antibiotics, peak-
concentrations of LPS may be shown, depending on the type of antibiotic used. ß-
lactam antibiotics, acting directly on the bacterial cell wall, induce higher endotoxin-
releases from Gram-negative bacteria compared with antibiotics with other working 
mechanisms. Within the group of ß-lactam antibiotics, differences in capacity to 
induce endotoxin release seem to be related to the affinity for Penicillin Binding 
Proteins (PBP) and the concomitant occurrence of different morphological changes of 
Gram-negative bacteria. Morphologically altered bacteria are called spheroplasts or 
filaments. Spheroplasts are large rounded bacteria, formed due to inhibition of PBP-
2, a receptor on the cytoplasmic membrane of Gram-negative bacteria. Filaments are 
viable, long strands of bacterial cell mass, formed after blocking of PBP-3. This 
alteration of morphology is caused by the inability of bacilli to septate after doubling 
of bacterial cell mass. PBP-1 inhibition leads to a fast lysis of bacteria, without 
preceding morphological changes. Chapter 3 describes our first in-vitro experiments 
on the influence of antibiotic type, concentration and dosing schedule on endotoxin-
releases during the first hours of treatment. We used an in-vitro dilution model to 
compare continuous and declining concentrations of 3 ß-lactams with different PBP-
affinities in E. coli and P. aeruginosa cultures. As expected, the highest endotoxin 
concentrations were observed during exposure to aztreonam and ceftazidime, the 
PBP-3-specific filament-inducing agents. Remarkably however, ceftazidime caused 
filament formation in E. coli at low concentrations, which was related to initially low 
total endotoxin concentrations. These concentrations rose to very high levels after 4 
h of exposure to this concentration of ceftazidime, while the concentration of free 
endotoxin remained low. Differences between continuous and intermittent schedules 
of ceftazidime became clear when concentrations of 40 x MIC and higher were 
applied. Continuous exposure of bacteria to ceftazidime led to effective bacteriolysis 
without filament formation, which was related to low total endotoxin contents with a 
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high percentage of free endotoxin. Declining concentrations of ceftazidime induced 
filaments and concomitant high endotoxin-patterns. This observation may be ex-
plained the dual affinity of ceftazidime for PBPs: at low concentrations PBP-3 affinity 
predominates, at higher concentrations PBP-1 is inhibited. In P. aeruginosa cultures, 
ceftazidime induced filaments at 5 x as well as 50 x MIC, at both continuous and 
declining dosages. From these studies we concluded that the concentration at which 
the switch from PBP-3 to PBP-1 binding occurs can also be dependent on the bacte-
rial isolates studied. 
Imipenem, a PBP-1 and PBP-2 inhibiting antibiotic, induced spheroplasts and rapid 
cell lysis, accompanied by significant lower endotoxin-concentrations, without differ-
ences between continuous and declining antibiotic concentreations. 
The carbapenem antibiotic meropenem has affinity for PBP-2 and PBP-3. As de-
scribed in chapter 4, we performed an in-vitro study to investigate the concentra-
tions at which filaments can be induced in E. coli ATCC 25922, P. aeruginosa ATCC 
27853 and K. pneumoniae ATCC 43816. In contrast to reports in the literature, those 
isolates turned out to form spheroplasts, even at concentration levels far below MIC. 
These spheroplasts remained viable, even after 24 h of exposure to meropenem. 
Cefotaxime and ceftazidime are ß-lactams of the oxyimino-group and show a dose-
dependent affinity for PBP-3 and -1. PBP-3 binding occurs at low concentrations, at 
higher concentrations PBP-1 inhibition occurs. In chapter 5, we describe an in-vitro 
study, comparing 8 concentration levels of ceftazidime and cefotaxime in 37 cultures 
of E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter spp.. As antibiotic resis-
tance by extended spectrum ß-lactamase (ESBL) producing strains of Enterobacteri-
aceae is an emerging problem in clinical practice, 14 ESBL-positive strains of E. coli 
and K. pneumoniae were included in this series. 
Patterns of filament-induction could be recognized easily: E. coli and K. pneumoniae 
induced filaments at low concentrations, which is probably related to their low MICs 
for both antibiotics. Pseudomonas and Acinetobacter strains showed filaments up to 
clinically relevant concentrations of 50 x MIC. So, filament induction seems to be not 
only antibiotic-dependent, but also bacterial family, genus or strain dependent. 
It should be emphasized that filament induction could also be shown in relative or 
absolute insusceptible microorganisms. ESBL does not protect bacilli against filament 
formation. This may cause additional unexpected risks during empirical antibiotic 
treatment of Gram-negative infections in clinical practice. 
To investigate the in-vivo implications of filament formation, we developed a neutro-
penic murine model. 
In chapter 6, survival, bacterial growth and spread, local and systemic endotoxin-
concentrations and pro-inflammatory cytokine profiles after intramuscular administra-
tion of filaments, spheroplasts and rods are described. Bacteria were incubated in-
vitro in the presence 0.5 x MIC concentrations of ceftazidime, meropenem or saline, 
to produce bacterial filaments, spheroplasts or rods, respectively. In line with our 
findings described in chapter 3, the inoculum containing filaments showed higher 
amounts of total endotoxin. In this study, spheroplasts contained more endotoxin 
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than controls, though not as much as filaments. This was contrasting with our earlier 
in-vitro studies, which showed equal endotoxin contents of rods and spheroplasts. 
This finding may be explained by the fact that we induced spheroplasts with PBP-2 
and -3 specific meropenem. In previous studies imipenem/cilastatin, which has 
affinity for PBP-1 and PBP-2, was applied. Apparently, meropenem-induced sphero-
plasts behave slightly more like filaments. 
Twentyfour hours after inoculation, filaments and spheroplasts turned out to have 
changed to rods, with an equal viability as unexposed bacteria, as shown by compa-
rable intramuscular cfu counts, endotoxin and cytokine concentrations. Remarkably, 
a difference in systemic spread was observed, with significant higher bacterial counts 
in livers of mice challenged with rod-shaped bacilli. This may be explained by a 
diminished migratory capacity of morphologically altered microorganisms. 
In this model, we were able to show significant correlations between muscle en-
dotoxin, plasma endotoxin and circulating pro-inflammatory cytokines (TNF-α and IL-
6). 
In studies described in chapter 7, we compared a peritonitis (ip) versus an intra-
muscular (im) infection model in neutropenic mice, with respect to inducibility of 
morphological changes in-vivo, severity and spread of infection and comparison of 3 
staining techniques. We were able to induce bacterial filaments and spheroplasts in a 
reproducable manner in both in-vivo models. 
. Bacterial morphology could easily be visualized intraperitoneally and in thigh muscle 
sections after haematoxylin-eosin, Gram’s or fluorescent acridine orange staining 
techniques. In liver and spleen these staining techniques did not allow identification 
of bacteria, despite of the presence in significant amounts of bacteria. 
In the im model, cfu counts were less variable compared with the ip model. Another 
problem we encountered in the ip model was a severe systemic dissemination of the 
infection, leading to severe illness of mice, severly hampering plasma sampling for 
analysis of endotoxin and cytokines. So, for both reasons, we judged the im model to 
be superior for the purpose of our studies. 
In both models we compared the effects of administration of aztreonam, ceftazidime, 
meropenem and imipenem iv in the tail vein during E. coli sepis. Significantly ele-
vated circulating cytokine concentrations were shown in mice treated with both 
filament-inducing antibiotics (aztreonam or ceftazidime), which may be attributable 
to higher endotoxin releases. When both spheroplast-inducing agents were com-
pared we observed a trend towards higher circulating pro-inflammatory cytokine 
concentrations in meropenem-treated mice, compared with imipenem. This is in line 
with the finding that meropenem-induced spheroplasts seem to contain more en-
dotoxin than imipenem-induced spheroplasts, as explained in chapter 6. 
Since the in-vitro studies showed that filament formation can be antibiotic-, dose- or 
regimen-dependent, we studied different dosing schedules in the in-vivo murine 
sepsis model. These studies are described in chapter 8. We titrated ceftazidime 
concentrations from 10 mg/kg up to filament-preventing levels, which turned out to 
be 80 mg/kg ceftazidime iv for E. coli infections. Interestingly, bolus treatment could 
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not prevent filament formation, despite of serum peak-concentrations of 486 mg/L 
(1944 x MIC). Obviously not the concentration, but merely the duration of antibiotic 
exposure plays a role in filament induction. 
Different dosing regimens turned out to have major implications for the cytokine 
responses of the host. Significantly higher pro-inflammatory cytokine concentrations 
were found in serum of mice with E. coli and P. aeruginosa sepsis receiving continu-
ous treatment. Apparently, these mice are exposed of to higher concenteratons of 
free bacterial endotoxin, which may be explained by an efficient bacteriolysis with 
sudden, high free endotoxin releases. This observation is in line with the findings in 
the in-vitro dilution experiments, described in chapter 3. The relative inaccessibility 
of the host defense system to endotoxin molecules present in filamentous cells in the 
focus of infection, may explain the very low cytokine responses in mice treated with 
bolus injections. By this observation, we hypothesize that further antibiotic therapy 
could have negative effects due to the possibility of a postponed, but higher en-
dotoxin and cytokine response. To investigate whether the difference between 
continuous and bolus administration of a ß-lactam antibiotic is unique for filament-
inducing antibiotics, we extended our studies to continuous or bolus treatment with 
meropenem. Interestingly, continuous treatment with this PBP-2 specific ß-lactam 
also led to higher cytokine responses, though not as high as during PBP-3 specific 
ceftazidime treatment. We conclude that, continuous administration leads to more 
effective bacteriolysis during the first hours of antibiotic treatment, irrespective of 
PBP-binding patterns. 
In chapter 9, we compared the morphology of in-vivo induced filaments after a 
second dose of ceftazidime, tobramycin or saline. Until 1 h after a second dose, 
filaments were still present, but filaments exposed to second ceftazidime injections 
showed longer forms, accompanied by significant higher circulating cytokine concen-
trations compared with saline-exposed filaments. This aims at augmentation of the 
endotoxin-contents of those filaments. 
In another series of studies, we pretreated E. coli bacteria with either continuous iv 
infusions or iv bolus injections of ceftazidime 80 mg/kg, in order to obtain filamen-
tous and non-filamentous bacteria, respectively. Four h later, high doses of mero-
penem were administered in order to cause filament lysis. As already described in 
chapter 8, continuously treated mice did not contain intramuscular filaments and 
showed high circulating cytokine concentrations. These pro-inflammatory cytokines 
rose to even higher levels after meropenem treatment. Apparently, intramuscular 
bacterial filaments may somehow be protected to lysis by meropenem initially. 
Nevertheless, we expect that these mice with filaments at the infection site run the 
risk of a postponed, but high LPS-release during further antibiotic treatment. 
In conclusion, the studies presented in this thesis show that antibiotic-induced 
bacterial filament formation, a phenomenon which is widely present in Gram-
negative bacterial strains including ESBL-producing strains, may have negative 
effects on the host. Antibiotic choice, concentrations, continuous dosing schedules 
and combination therapy largely influence these morphological alterations and 
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concomitant endotoxin and cytokine releases. Continuous dosing seems to be advan-
tageous not only in filament-inducing ß-lactams, but also in spheroplast-inducing 
antibiotics. These findings show that the choice of initial empirical antibiotic regimen 
may be essential during sepsis treatment. A series of unanswered questions remain 
for any investigator exploring the complex field of sepsis research, such as: can 
murine results be extrapolated to human infections? In what manner can we trans-
late our short-term results to long-term changes in bacterial and host behaviour and 
final clinical outcome? 
Future studies should aim at measurements of bacterial and host parameters during 
longer periods of sepsis in murine models, especially collecting direct parameters of 
efficacy. Despite of the many methodological problems of sepsis research, the in-vivo 
consequences of this phenomenon in human infections should be further investi-
gated. 
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Samenvatting 
 
In de loop van de afgelopen eeuw is de toepassing van antibiotica de hoeksteen van 
de medicamenteuze therapie van bacteriële infecties geworden. Echter, kort na de 
introductie van deze middelen werd al melding gemaakt van het risico van ernstige 
klinische achteruitgang van patiënten onmiddellijk na de start van deze therapie. 
Enige jaren later werd duidelijk dat dit verschijnsel waarschijnlijk verklaard kon 
worden door de plotselinge vrijmaking van toxische componenten van de bacterie, in 
het bijzonder het in de celwand van de Gram-negatieva bacterie in ruime mate 
aanwezige endotoxine (lipopolysaccharide, LPS). Tijdens de vorige eeuw zijn de 
structurele kenmerken en andere eigenschappen van dit molecuul ontrafeld. In 
hoofdstuk 2 wordt een kort overzicht gegeven van de belangrijkste biologische 
mechanismen van LPS-toxiciteit. Ook gedurende normale groei van Gram-negatieve 
bacteriën komen kleine hoeveelheden LPS vrij. Echter, bij blootstelling van deze 
bacteriën aan antibiotica kunnen hoge piekconcentraties voorkomen, afhankelijk van 
het soort antibioticum dat toegepast wordt. Het werkingsmechanisme van ß-lactam 
antibiotica behelst directe binding en daarmee blokkade van receptoren in het 
cytoplasma membraan. Deze receptoren worden penicilline bindende eiwitten [Peni-
cillin Binding Proteins (PBP)] genoemd. Blokkade van deze PBPs leidt tot een blokka-
de van processen die belangrijk zijn voor de celdeling. Met name de synthese van 
celwand componenten komt in het gedrang bij toepassing van middelen uit deze 
klasse. Daar deze antibiotica ter plaatse van de celwand werken, kunnen zij tot een 
snelle vrijmaking van hoge concentraties endotoxine leiden, zeker in vergelijking met 
antibiotica met andere werkingsmechanismen. Desalniettemin bestaan ook binnen de 
inmiddels vrij grote groep van ß-lactam antibiotica belangrijke verschillen in de 
mogelijkheid tot endotoxinevrijmaking, hetgeen lijkt samen te hangen met de affini-
teit van het individuele middel voor één van de penicilline bindende eiwitten. Deze 
penicilline bindende eiwitten hebben belangrijke functies bij het maken van de 
nieuwe celwandcomponenten gedurende groei en deling. ß-lactam antibiotica blokke-
ren deze eiwitten en induceren daardoor morfologische veranderingen bij de bloot-
gestelde groeiende micro-organismen. Deze morfologisch afwijkende bacteriën 
noemen we sferoplasten en filamenten. Sferoplasten zijn grote afgeronde bacteriën, 
die gevormd worden na blootstelling van de Gram-negatieve staafvormige bacteriën 
aan antibiotica die PBP-2 blokkeren. Filamenten zijn zeer lange strengvormige 
bacteriën, die gevormd worden doordat PBP-3 geblokkeerd wordt, waardoor het 
micro-organisme niet meer in staat zich in tweeën te scheiden (septeren) nadat de 
celmassa verdubbeld is tijdens groei. Er zijn ook ß-lactam antibiotica die PBP-1 
blokkeren, hetgeen leidt tot snel in fragmenten uiteenvallen van de geëxposeerde 
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bacterie, zonder voorafgaande morfologische verandering. In hoofdstuk 3 worden 
de eerste studies beschreven over het effect van drie ß-lactam antibiotica met 
verschillende PBP-bindings karakteristieken, de toegepaste concentraties en de 
doseerschemas op endotoxine-inhoud en -vrijmaking door een Escherichia coli en 
Pseudomonas aeruginosa stam, gedurende de eerste uren van therapie. Hierbij werd 
gebruik gemaakt van een in-vitro dilutie-model om het effect van dalende antibioti-
cumspiegels te kunnen vergelijken met continue expositie van de bacterie aan het 
antibioticum. Conform onze hypothese werden uiteindelijk de hoogste endotoxine-
concentraties gevonden gedurende de toepassing van de PBP-3 specifieke middelen 
aztreonam en ceftazidime. Opmerkelijk was het feit dat alleen bij lage concentraties 
ceftazidime filamenten gevormd werden, waarbij in de initiële fase lage concentraties 
niet-celgebonden endotoxine aangetroffen werden, die echter na enkele uren tot 
zeer hoge waarden konden stijgen. Deze observatie lijkt verklaarbaar door het feit 
dat aanvankelijk endotoxine moleculen ingebouwd en dus vastgehouden worden in 
de celwand. Pas later volgt het lyseren van de celwand, waarbij de endotoxine 
moleculen vrijkomen. Verschillen tussen continue expositie versus dalende ceftazidi-
me concentraties werden voor de E. coli stam duidelijk vanaf concentraties van 40 x 
MIC en hoger. Dit bleek te maken te hebben met het feit dat gedurende continue 
bacteriële expositie aan dit concentratieniveau in plaats van filamentvorming een 
snelle effectieve bacteriolyse optrad, hetgeen leidde tot beperkte mogelijkheden tot 
endotoxine release. Deze bevinding wordt verklaard door de tweeledige concentratie-
afhankelijke affiniteit van ceftazidime voor PBPs heeft: bij voldoend hoge continue 
concentraties wordt een PBP-1 effect gezien. Tijdens een dalende ceftazidime con-
centratie overheerst het PBP-3 effect, waardoor dus wel filamenten en hoge endo-
toxineconcentraties gezien werden. In de experimenten met P. aeruginosa werden 
geen verschillen gevonden tussen bacterieculturen blootgesteld aan dalende versus 
stabiele antibioticumconcentraties, zowel op het concentratieniveau 5 x als 50 x MIC. 
Wij concluderen hieruit dat de switch van PBP-3 naar PBP-1-effect kennelijk ook kan 
variëren per stam of genus. 
Imipenem, een carbapenem met zowel affiniteit voor PBP-1 als PBP-2, induceerde 
sferoplasten. Bij de hoogste dosis (50 x MIC) in het Pseudomonas experiment trad 
een snelle lysis, zonder opvallende spheroplastvorming op, passend bij met name het 
PBP-1 inhibitie effect. Dit leidde tot lage antibioticum-geinduceerde endotoxine 
vrijmaking, zowel bij continue als dalende spiegels, onafhankelijk van het concentra-
tieniveau. Uit deze studies is duidelijk gebleken dat sommige ß-lactam antibiotica in 
staat zijn Gram-negatieve bacteriën aan te zetten tot vorming van grote hoeveelhe-
den filamenten met potentieel gevaarlijke hoeveelheden toxisch lipopolysaccharide in 
de celwand, hetgeen wel kan varieren per antibioticum, doseerniveau, verloop van 
spiegels en de geëxposeerde bacteriestam. 
Meropenem is een antibioticum uit de carbapenem-groep met affiniteit voor PBP-2 en 
PBP-3. In hoofdstuk 4 beschrijven we een studie waarin we onderzochten bij welke 
concentraties het PBP-2 of het PBP-3 effect zichtbaar gemaakt kon worden. In 
tegenstelling tot eerdere mededelingen in de literatuur, konden we bij de door ons 
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geteste stammen (E. coli ATCC 25922, P. aeruginosa ATCC 27853, K. pneumoniae 
ATCC 43816) alleen sferoplastvorming of bacteriolysis teweeg brengen, op 9 concen-
tratiesniveaus, gedurende 24 uur expositie aan meropenem. Deze sferoplasten 
bleken ook na 24 uur blootstelling aan meropenem in veel gevallen nog vitaal. 
Zoals we reeds constateerden in hoofdstuk 3, is ceftazidime een middel met een 
dosis-afhankelijke affiniteit voor PBP-3 en PBP-1. Aangezien we reeds het vermoeden 
hadden dat het omslagpunt van deze bindingseigenschappen wel eens zou kunnen 
variëren tussen bacteriestammen voerden wij een groot experiment uit, waarbij we 
naast ceftazidime nog een tweede ß-lactam onderzochten (cefotaxim) met dosisaf-
hankelijk PBP-3 en -1 affiniteit. In deze studies, welke beschreven worden in hoofd-
stuk 5 werden 37 stammen van E. coli, Klebsiella spp., P. aeruginosa en Acinetobac-
ter spp. gedurende 4 uur blootgesteld aan 8 verschillende concentraties van ceftazi-
dime of cefotaxim. Daar we inmiddels weten dat de productie van Extended Spec-
trum ß-lactamases (ESBL) door Enterobacteriaceae een toenemend klinisch relevant 
probleem vormt, werden ook 14 ESBL-positieve stammen van E. coli en K. pneumo-
niae in deze analyse betrokken. Er werden duidelijke patronen gezien: E. coli en K. 
pneumoniae vormden filamenten bij lage concentraties van beide middelen, hetgeen 
waarschijnlijk gerelateerd is aan de lage MIC van deze middelen bij deze micro-
organismen. Pseudomonas- en Acinetobacter-stammen lieten filamentvorming zien 
tot concentraties van wel 50 x MIC, hetgeen ook bij klinische toepassing van deze 
middelen relevante concentraties zijn. We concluderen dan ook dat filament vorming 
niet alleen antibioticum afhankelijk is, maar ook kan variëren per bacterie familie, 
genus of stam. Hierbij dient nog eens benadrukt te worden dat inductie van filamen-
ten ook aangetoond kan worden bij absoluut of relatief ongevoelige micro-
organismen. De aanwezigheid van ESBL vormt geen bescherming tegen het aanzet-
ten van bacteriën tot filament vorming. Dit zou in de klinische praktijk kunnen leiden 
tot bijkomende en onverwachte risico’s gedurende de behandeling van Gram-
negatieve infecties met relatief ongevoelige microorganismen. 
Teneinde de in-vivo consequenties van deze bevindingen verder te exploreren werd 
tijdens het vervolg van dit onderzoek een in-vivo model ontwikkeld in neutropene 
muizen. In neutropene muizen kon eenvoudig een snel verlopend reproduceerbaar 
sepsis beeld veroorzaakt worden. Bovendien is bekend uit de literatuur dat neutro-
pene muizen gevoeliger zijn voor de effecten van endotoxine. 
In hoofdstuk 6 worden de effecten beschreven van intramusculaire injecties van in-
vitro gemaakte filament-, sferoplast- en staafvormige E. coli bacteriesuspensies. 
Groei, systemische verspreiding en morfologie van het microorganisme werden 
bestudeerd. Bij de gastheer werd gekeken naar overlevingsduur, circulerende en 
locale endotoxineconcentraties en de cytokinerespons (TNF-α en interleukine-6). De 
pro-inflammatoire cytokines werden gemeten als maat voor de gastheerrespons. 
Deze parameters lijken ook in andere studies goed te corresponderen met de ernst 
en de uitkomst van infecties. Overeenkomstig onze bevindingen beschreven in 
hoofdstuk 3, bleken de filamentsuspensies meer endotoxine per milliliter te bevat-
ten dan staafvormige bacteriën. In tegenstelling tot onze eerdere in-vitro studies 
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bleken ook de sferoplastsuspensies iets meer endotoxine te bevatten dan staven, 
echter veel minder dan filamenten. Een verklaring voor dit feit zou kunnen liggen in 
het feit dat de sferoplasten in de studie van hoofdstuk 6 geïnduceerd werden door 
incubatie van de bacteriën met meropenem, een middel met PBP-2 en een milde 
PBP-3 affiniteit, terwijl in de in-vitro studies beschreven in hoofdstuk 3 imipe-
nem/cilastatin werd toegepast om sferoplasten te vormen. Dit laatstgenoemde 
middel heeft PBP-2- gecombineerd met een lichte PBP-1-affiniteit. Blijkbaar induceert 
meropenem speroplasten met iets meer filament eigenschappen. 
Tijdens deze studie werd gezien dat filamenten en speroplasten na 24 uur, in afwe-
zigheid van het antibioticum, weer staafvormen hadden aangenomen en blijkens de 
bevindingen bij kweek, endotoxine en cytokine-bepalingen, even vitaal bleken te zijn 
als bacteriën die tevoren niet aan antibiotica blootgesteld waren. Opmerkelijk was 
wel de observatie dat morfologisch veranderde bacteriën slechter in staat waren tot 
systemische verspreiding, hetgeen bleek uit significant hogere kiemgetallen in 
leverkweken van met staven ingespoten muizen. Kennelijk geeft expositie van het 
micro-organisme aan ceftazidime of meropenem aanleiding tot veranderde migratie 
capaciteit. In deze studies konden we een correlatie laten zien tussen locaal endo-
toxine, plasma endotoxine en circulerende pro-inflammatoire cytokines. 
In de studies beschreven in hoofdstuk 7, vergeleken we een E. coli peritonitis-
model en een intramusculair infectie model in neutropene muizen. Met name werd 
de mogelijkheid van in-vivo productie en aantonen van filamenten en sferoplasten 
onderzocht. Drie verschillende kleuringstechnieken werden vergeleken. Tevens werd 
de ernst en verspreiding van beide infectie-routes vergeleken. Het lukte inderdaad 
om in de neutropene muis onder invloed van ceftazidime of meropenem filamenten 
en sferoplasten te laten ontstaan, zowel in de dijspier als intraperitoneaal. Deze 
morfologisch afwijkende bacteriën bleken in de dijspier en op het peritoneum fraai 
aantoonbaar door middel van haematoxylin-eosine, Gram of (fluorescerend) acridine 
oranje kleuringen. In lever en milt bleken deze drie kleuringstechnieken niet in staat 
bacteriën te visualiseren, ondanks de zekere aanwezigheid van significante bacterie-
concentraties. In het intramusculaire infectiemodel bleken de kiemgetallen veel 
minder variatie te tonen. Bovendien bleek er in het intraperitoneale model veel meer 
sprake van systemische verspreiding van de infectie, waardoor de overleving van de 
muizen zeer beperkt bleek. Door dit laatste fenomeen waren nauwkeuringe metingen 
van plasma-endotoxine en cytokineconcentraties ook niet mogelijk in dit model, 
aangezien slechts zeer beperkte hoeveelheden plasma verkregen konden worden uit 
de bloedbaan van deze ernstig zieke muizen. We vergeleken de effecten van aztreo-
nam, ceftazidime, meropenem of imipenem intraveneus bij intraperitoneale en 
intramusculaire E. coli infecties. Significant verhoogde plasma cytokineconcentraties 
konden aangetoond worden bij behandeling met filament inducerende antibiotica 
(aztreonam of ceftazidime), vergeleken met controles. Bij toepassing van sphero-
plast-inducerende antibiotica werd een trend gezien van hogere cytokinespiegels bij 
meropenem, vergeleken met imipenem. Deze bevinding suggereert wederom dat 
meropenem-geïnduceerde spheroplasten meer endotoxine bevatten dan imipenem-
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geïnduceerde spheroplasten, hetgeen te maken kan hebben met een verschil in PBP 
bindings patroon tussen beide carbapenems. 
Vanwege de bovengenoemde nadelen van het intraperitoneale muis model werden 
de studies van hoofdstuk 8 en 9 alleen uitgevoerd in het intramusculaire neutrope-
ne muis model. 
Daar we al in onze in-vitro studies (hoofdstuk 3) hadden laten zien dat filament-
vorming antibioticum-, dosering- en doseerregime-afhankelijk was, werd in de 
volgende stap van dit onderzoek het effect van variërende behandelschema’s van 
antibiotica met verschillende PBP-affiniteit in het in-vivo model onderzocht. In 
hoofdstuk 8 worden de studies beschreven waar in we ceftazidime bolusinjecties 
vergeleken met continu-infusie intraveneus in de staartvene, met als doel het vinden 
van het omslagpunt waarboven filament vorming voorkomen kan worden bij dit 
antibioticum met dosis-afhankelijke PBP-affiniteit. Dit dosisniveau bleek voor ceftazi-
dime continu-infusie te liggen op 80 mg/kg bij E. coli sepsis in muizen. Verrassend 
was de bevinding dat intraveneuze bolusinjecties met ceftazidime niet in staat bleken 
filamentvorming te voorkomen, ondanks gemeten serum piek-concentraties van 486 
mg/L, wat 1944 x boven de MIC van deze bacteriestam uitkomt. Kennelijk is niet 
alleen de concentratie, maar ook duur van expositie van het micro-organisme aan 
het antibioticum van belang bij filament inductie. 
Verschillen in doseerschema’s van niet alleen ceftazidime, maar ook van het PBP-2 
bindende meropenem bleken belangrijke implicaties te hebben voor de cytokineres-
pons van de gastheer. Zowel bij E. coli als bij P. aeruginosa sepsis werden significant 
hogere plasma cytokineconcentraties gevonden bij continu behandelde muizen. 
Kennelijk wordt het immuunsysteem van de gastheer bij continu-infusie blootgesteld 
aan hogere concentraties vrijgemaakt endotoxine, waarschijnlijk door een meer 
effectieve bacteriolysis in deze situatie. Deze bevinding komt overeen met onze 
resultaten van de in-vitro studies van hoofdstuk 3. De relatieve onbereikbaarheid 
van het in de bacterie celwand gebonden endotoxine in de filamenten in het infectie-
focus zou een verklaring kunnen vormen voor deze observatie. Op grond van deze 
gegevens kwamen wij tot de hypothese dat aanvullende antibiotische behandeling 
wel eens zeer nadelig zou kunnen zijn in het geval dat filamentvorming reeds een feit 
is, vanwege de mogelijkheid van vrijmaking van zeer hoge concentraties endotoxine 
uit de wand van de filamenten. Dit zou kunnen leiden tot een weliswaar uitgestelde, 
maar verhoogde endotoxine- en cytokinerespons bij de gastheer, met de daarbij 
behorende negatieve klinische effecten. 
In hoofdstuk 9 behandelen we de resultaten van studies gericht op het blootstellen 
van reeds gevormde filamenten aan vervolgtherapie. We keken naar veranderingen 
in morfologie van de filamenten, kort na een tweede gift ceftazidime of een gift 
tobramycine. In elk geval werden tot een uur na de tweede gift nog steeds filamen-
ten gevonden in de dijspier. Indien de filamenten behandeld werden met nogmaals 
een dosis ceftazidime bleken ze veel langer te worden, hetgeen gepaard ging met 
hogere cytokineconcentraties in het plasma van de gastheer. Dit wijst op een sterke-
re blootstelling van de gastheer aan endotoxine in deze situatie. Na tobramycine, een 
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aminoglycoside, werden de filamenten korter, hetgeen bleek te leiden tot minder 
hoge cytokine spiegels. Endotoxine concentraties in plasma bleken niet te verschillen 
tussen de groepen. Een mogelijke verklaring daarvoor is het feit dat de plasma 
endotoxine concentratie toch geen goede afspiegeling is van de totale hoeveelheid 
aanwezige toxische bacteriële producten in de gastheer. Daarbij spelen mogelijk 
klaring en binding aan plasma- en weefselcomponenten een rol.  
In een andere serie experimenten, eveneens beschreven in hoofdstuk 9, werden 
muizen geïnfecteerd met E. coli aanvankelijk behandeld met continu-infusie of 
bolusinjecties ceftazidime, op een concentratieniveau (80 mg/kg) waarbij continu-
infusie géén en bolusinjecties wel filamentvorming veroorzaken. Na 4 uur voorbe-
handeling werden de muizen behandeld met een hoge dosering meropenem. Net 
zoals in de experimenten van hoofdstuk 8 constateerden we dat na 4 uur continu-
infusie de cytokinespiegels duidelijk hoger waren dan bij de met een eenmalige 
injectie behandelde muizen. Deze cytokinespiegels bleken na meropenem nog verder 
door te stijgen in de continu behandelde groep. Mogelijk zijn de filamenten in de 
dijspier nog gedurende enige tijd beschermd tegen lysis door meropenem. Dat 
neemt niet weg dat er een potentieel risico lijkt te bestaan op een uitgestelde, maar 
wellicht versterkte endotoxine release, welke negatieve klinische consequenties tot 
gevolg zou kunnen hebben. 
 
Concluderend laten de studies beschreven in dit proefschrift zien dat de door bepaal-
de ß-lactam antibiotica geïnduceerde morfologische veranderingen van bacteriën, 
een fenomeen dat uitgebreid aanwezig is in tal van Gram-negatieve micro-
organismen inclusief ESBL-vormende stammen, effecten hebben op de gastheer. Niet 
alleen de antibioticumkeuze, maar ook de dosering, doseerschema’s en de toepas-
sing van combinatietherapie hebben duidelijke invloeden op de morfologie, de 
endotoxinevrijmaking en de immunologische respons van de gastheer. Continu 
infusie van ß-lactam antibiotica lijkt gunstig, niet alleen bij de middelen die filamen-
ten induceren door PBP-3 binding, maar ook bij middelen uit dezelfde klasse die 
spheroplasten laten ontstaan doordat ze op de PBP-2-receptor aangrijpen. Deze 
experimenten maken aannemelijk dat de keuzes die gemaakt worden bij het starten 
van empirische antibiotische therapie bij sepsisbehandeling belangrijke consequen-
ties kan hebben. Dat neemt niet weg dat ook dit onderzoek een serie van vragen 
opwerpt zoals: kunnen gegevens uit proefdieronderzoek geëxtrapoleerd worden naar 
humane infecties? Op welke manier beïnvloeden de door ons bestudeerde korte 
termijn effecten het verdere gedrag van de ziekteverwekker, de gastheer en het 
uiteindelijke beloop van de infectie? 
Toekomstig onderzoek zou zich dan ook moeten richten op het meten van bacteriële 
en gastheer parameters gedurende het verdere verloop van ernstige Gram-negatieve 
infecties, met name ook door middel van het verzamelen van directe parameters van 
effectiviteit. Ondanks de vele lastige methodologische problemen bij sepsisonder-
zoek, zouden ook de consequenties van antibioticum-geinduceerde morfologische 
veranderingen bij humane sepsis verder onderzocht dienen te worden. 
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Appendix  Full colour illustrations
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Chapter 1 
 
Figure 3. Anaesthesized mice during continuous infusions in the tail vein
 
 
Chapter 2 
 
Figure 2. Gram-negative bacterial endotoxin (lipopolysaccharide, LPS) 
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Figure 3. Schematic representation of the E.coli envelope14 
Abbreviations: LPS: lipopolysaccharide; MDO: membrane-derived oligosaccharides; 
Kdo: 3-deoxy-d-manno-oct-2-ulosonic acid; PPEtn: phosphoethanolamine  
 
 
Figure 4. Scheme of inflammatory responses in sepsis1 
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Chapter 4 
   
Figure 2.  
A. Spheroplasts of E. coli after exposure to meropenem 0.5 x MIC 
B. Filaments of E. coli after exposure to ceftazidime 0.5 x MIC 
 
A B
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Chapter 6 
 
Figure 2. Rods, short and long filaments (1000 x) of E. coli, P. aeruginosa, K. pneumoniae and A. baumanii 
 
Chapter 7 
 
Figure 2. Intramuscular E. coli filaments, acridine orange (1000 x) after ceftazidime iv 
E. coli
K. pneumoniae
P. aeruginosa
A. baumanii
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Chapter 8 
 
Figure 1. Filaments in thigh muscle (HE-stained) 
 
 
Chapter 9 
Figure 1.  
A. Short filaments (3-10 rods) after exposure of ceftazidime-induced filaments to tobramycin 
B. Long filaments (>10 rods) after exposure of ceftzidime-induced filaments to a second dose 
of ceftazidime 
 
 
 BA
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Dankwoord 
 
 
Eindelijk ligt hier dan toch dit boekje. Het was voor mij een langdurig traject, maar ik 
realiseer me terdege dat dit niet gelukt was zonder de hulp van vele mensen in de 
afgelopen jaren.  
 
De eerste stappen van dit onderzoek werden gezet in 1994. De eerste studies 
vormden een vervolg op het onderzoek van mijn copromotor Ton Dofferhoff. Ton, ik 
wil je hartelijk danken voor je enthousiaste hulp en inzet, zelfs bij het uitvoeren van 
het handwerk in het microbiologisch laboratiorium. Volgens mij is het oude analis-
tenbloed nog steeds bij jou aanwezig. Ik hoop van harte dat ook na deze promotie 
onze samenwerking zal voortduren. De weg tussen Nijmegen en Maastricht lijkt 
intussen toch wel duidelijk korter geworden. 
 
Prof. Dr. J.W.M. van der Meer: beste Jos, hoewel je in het begin meer zijdelings 
betrokken was bij dit Canisius-project, heb je op de juiste momenten de duw in de 
goede richting weten te geven. Mede dankzij die steun ligt nu dit boekje hier. 
 
Dr. J.W. Mouton: Johan, hartelijk dank voor de gastvrijheid op jullie laboratorium. Op 
de vreemdste tijden kon ik er terecht voor mijn experimenten, waarbij ook altijd 
weer adequate hulp geboden werd. Je hebt me met name kunnen helpen aan de 
farmacokinetische data en de computerprogramma’s voor de data-analyse en statis-
tische bewerkingen. 
 
Het bestuur van het SWOIG heeft ons diverse subsidies toegekend. Het is bijzonder 
dat we daardoor als niet-academische afdeling dit soort basale wetenschappelijke 
experimenten hebben kunnen uitvoeren.  
 
Mijn voormalige opleider Dr. Roy Go wil ik hier speciaal noemen: niet alleen was jij 
degene die mij ervan heeft overtuigd dat interne geneeskunde het allermooiste vak 
is, maar ook was jij het die mij op dit onderzoekspad zette. Ik waardeer je zeer om 
de door de jaren heen steeds weer getoonde belangstelling en aanmoedigingen.  
 
Dr. Hans Vollaard, apotheker: met name in de beginfase heb je me geholpen met het 
nadenken over de farmacokinetische vraagstukken van mijn modellen; ook zorgde je 
ervoor dat ik steeds de farmaca voor mijn muizen kreeg. Op de ECCMID was je de 
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trouwste bezoeker van mijn posterpresentaties en daarbij wist je steeds weer de 
juiste kritische vragen te stellen, waardoor ik weer nieuwe ideeën kreeg. 
 
Marcel Mravunac en Carla Wauters, pathologen CWZ: hartelijk dank voor al het werk 
wat op jullie laboratorium werd verricht; alle histologische plaatjes, inclusief de foto 
op de kaft van dit boek zijn door jullie gemaakt. 
 
Ineke Verschueren, analiste van het laboratorium Interne Geneeskunde UMCN: jij 
hebt enorm veel werk gehad aan de vele cytokinebepalingen.  
 
Maaike den Hollander heeft de antibioticum spiegel bepalingen verricht met de HPLC. 
 
Nico Jacobs, analist CWZ: samen hebben we uren zitten ploeteren met de endotoxi-
ne-bepaling. Het was lastig, maar heeft ons ook veel kennis opgeleverd.  
 
De medewerkers van het laboratorium medische microbiologie in het CWZ dank ik 
voor hun behulpzaamheid en interesse.  
 
De microbiologen van het Atrium MC, Els de Brauwer en Hans Wagenvoort, dank ik 
voor de geboden gastvrijheid op jullie laboratorium voor het uitvoeren van de laatste 
proeven van hoofdstuk 5. Met name heeft Tiny Rompen me daarbij veel geholpen.  
 
Bianca Lemmers, jij hebt de meest ingewikkelde proeven met mij samen gedaan. 
Jouw biotechnische assistentie was van grote waarde. Ik heb speciaal een foto 
toegevoegd aan hoofdstuk 1 om te laten zien wat we daar allemaal hebben zitten 
doen; daar liggen er maar drie, maar we konden het uiteindelijk ook met 8 muizen 
tegelijk! 
 
Maikel van Riel, Monique Bakker en Margot van den Brink hebben het microbiolo-
gisch werk op het dierenlaboratorium verricht. Met name het bij nacht en ontij 
kweken en enten van mijn stammen was een hele klus voor Maikel. 
 
De maatschap gaf mij de mogelijkheid om gedurende een periode in deeltijd te 
werken, zodat ik als “research-fellow” nog wekelijks naar Nijmegen kon. Met name 
mijn maten Leon Frenken en Hans Wolters dank ik voor het waarnemen van de 
afdeling, vooral op momenten dat ik weer eens klusjes te doen had voor dit proef-
schrift. 
 
Mijn jaarclub, Bas, Hugo, Vincent, Otto, Berend, Inne, Ronald: ik ben er trots op dat 
wij al meer dan 25 jaar een hechte vriendschap hebben. Eigenlijk had ik jullie ook in 
de opdracht van dit proefschrift willen betrekken, maar het staat voor buitenstaan-
ders wellicht wat vreemd als ik een proefschrift aan 12 mannen opdraag. Het is voor 
mij een groot genoegen dat twee van jullie mij zullen bijstaan als paranimf.  
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Mijn paranimfen Ronald Kempers en Bas Schreiner: tijdens onze scherm- en squash-
avondjes hadden we toch niet kunnen denken dat we 25 jaar later hier zouden staan 
met zijn drieën.  
 
Willy-Anne Nieuwlaat: niet alleen heb je me met je wekelijkse duw-telefoontjes flink 
gestimuleerd om tot dit resultaat te komen, maar je gaf me onder het genot van een 
goed glas wijn op cruciale momenten de juiste strategische adviezen. 
 
Mijn broer Arie: het is een overtuigende overwinning geworden, op mijn promotieda-
tum ben ik op de kop af 300 dagen jonger dan jij was op je promotiedatum. Ik dank 
je voor je nimmer aflatende belangstelling voor mijn vorderingen, maar vooral voor 
de sterke band die wij als broer en zus hebben.  
 
Mijn vader Jan Buijs is helaas overleden in 1984. Op een moment als dit realiseer ik 
me dat dit het zoveelste mooie moment is wat we niet meer samen hebben kunnen 
delen. Dat zelfde geldt voor mijn schoonouders Wil en Wim van Kraaij; zij waren 
altijd belangstellend naar de vorderingen van het onderzoek en bovendien zeer 
betrokken bij ons gezin. Mijn moeder dank ik omdat dat zij samen met mijn vader 
ervoor gezorgd heeft dat wij drieën, in een tijd dat dat nog niet vanzelfsprekend was, 
een goede opleiding hebben kunnen volgen. Hiervan hebben wij, tot op de dag van 
vandaag, dagelijks plezier. 
 
Ans, Wilma en Lizette: jullie zijn en waren voor ons en onze kinderen van onschatba-
re waarde; zonder jullie hulp zouden we het allemaal niet voor elkaar krijgen. 
 
Bas, Tom, Vincent en Joris: 4 van mijn 5 favoriete mannen. Mijn werkstuk is af! Dat 
is voor jullie waarschijnlijk net zo’n grote opluchting als voor mij. Ik zie jullie nu al 
rekenen hoeveel computer-uren dit kan opleveren. Ik geef toe, dit excuus heb ik niet 
meer, ik zal weer met nieuwe argumenten moeten komen. Zonder jullie was dit 
proefschrift misschien eerder af geweest, maar het leven zou er ook een stuk saaier 
op geworden zijn. Sinds jullie er zijn is het leven een feest! 
 
Tenslotte Dave, mijn geliefde en meest favoriete man: jij bent in de afgelopen jaren 
de enige geweest die bleef geloven in de succesvolle afronding van dit project. Je 
bleef maar roepen: “dat proefschrift is allang klaar, maar jij hebt het nog niet door”. 
Je had weer gelijk. 
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